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Mononuclear phagocytes in both the central nervous system and periphery are central to 
orchestrating innate immune responses to pathogens. The function of mononuclear phagocytes is tightly 
regulated by adenosine, an endogenous purine nucleoside, which is a ligand of four G protein-coupled 
adenosine receptors (ARs): A1AR, A2AAR, A2BAR and A3AR. Microglia, which are the main 
mononuclear phagocyte population in the central nervous system, are activated by pathogen-associated 
molecular patterns and produce proinflammatory cytokines, such as tumor necrosis factor-α, interleukin 
(IL)-6, and IL-12, and the anti-inflammatory cytokine IL-10. ARs have been shown to suppress TNF-α 
production by microglia, but their role in regulating IL-10 production has not been studied. Here, we 
demonstrate that adenosine augments IL-10 production by murine microglia activated by Toll-like 
receptor ligands while suppressing the production of proinflammatory cytokines. Our data from 
pharmacological experiments suggest that the stimulatory effect of adenosine on IL-10 production is 
mediated by the A2BAR. Mechanistically, adenosine augmented IL-10 mRNA accumulation by a 
transcriptional process. Using mutant IL-10 promoter constructs we showed that a cAMP responsive 
element binding protein (CREB)-binding region in the promoter mediated the augmenting effect of 
adenosine on IL-10 transcription. The role of CREB was confirmed by chromatin immunoprecipitation 
analysis and RNA interference. In addition, we showed that activation of p38 mitogen-activated protein 
kinase and phosphatidylinositol 3-kinase by adenosine was necessary for the stimulatory effect of 
adenosine on IL-10 production. In the periphery, adenosine had been shown to suppress the 
proinflammatory responses of classically activated macrophages, which are induced by Th1 cytokines. 
However, the role of adenosine in governing alternative macrophage activation, induced by the Th2 
cytokines interleukin IL-4 and IL-13 had been unknown. We have discovered that AR activation 
augments the IL-4 or IL-13-induced expression of alternative macrophage markers arginase-1, tissue 
inhibitor of matrix metalloproteinase-1 and macrophage galactose-type C-type lectin-1. The stimulatory 
effect of adenosine required primarily A2BARs. Of the transcription factors known to drive alternative 
macrophage activation, CCAAT-enhancer-binding protein  was required, while CREB and signal 
transducer and activator of transcription 6 were dispensable in mediating the effect of adenosine. 
Collectively, our results establish that A2BARs not only augment IL-10 production by classically activated 






A1AR  A1 adenosine receptor 
A2AAR A2A adenosine receptor 
A2BAR  A2B adenosine receptor 
A3AR  A3 adenosine receptor 
AD   Alzheimer’s disease 
AMP   adenosine 5’-monophosphate 
ADP   adenosine 5’-diphosphate 
ATP   adenosine 5’-triphosphate 
cAMP   cyclic adenosine 5’-monophosphate 
C/EBPβ  CCAAT-enhancer-binding protein  
ChIP   chromatin immunoprecipitation 
CNS  central nervous system 
CREB   cAMP responsive element-binding protein 
COPD  chronic obstructive pulmonary disease 
DC  dendritic cell 
DMEM  Dulbecco’s Modified Eagle Medium 
EAE   experimental autoimmune encephalomyelitis 
EC50   half maximal effective concentration 
ELISA  enzyme-linked immunosorbent assay 
EPAC   exchange protein directly activated by cAMP 
ERK  extracellular signal-regulated kinase 
FBS   fetal bovine serum 
GPCR  G protein coupled receptor 
HRP   horseradish peroxidase 
IB-MECA N6-(3-iodobenzyl)-adenosine-5′-N-methylcarboxamide 
IFN   interferon 
Ig   immunoglobulin 
iNOS  inducible nitric oxide synthase 
IL  interleukin 
JAK   janus-activated kinase 
JNK   c-Jun N-terminal kinase 
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KO   knockout 
LPS   lipopolysaccharide 
MAPK  mitogen-activated protein kinase 
mgl-1   macrophage galactose-type C-type lectin 
MIP   macrophage inflammatory protein 
MMP  matrix metalloproteinase 
NF-κB  nuclear factor kappa B 
NLR   NOD-like receptor 
NLRP3  NOD-like receptor P3 
NO   nitric oxide 
NOD   nucleotide-binding oligomerization domain 
PAMP  pathogen associated molecular pattern 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PGN   peptidoglycan 
PI3K  phosphatidylinositol 3-kinase 
PKA   protein kinase A 
PLC  phospholipase C 
PRR   pathogen recognition receptor 
RELM-α  resistin-like molecule-α 
SEM   standard error of the mean 
shRNA  small hairpin ribonucleic acid 
STAT   signal transducer and activator of transcription 
TH   T helper 
TG   thioglycollate 
TIMP-1  tissue inhibitor of metalloproteinase 
TLR  toll-like receptor 
TNF-α  tumor necrosis factor alpha 
VEGF  vascular endothelial growth factor 





3.1. Mononuclear phagocytes 
 
The central components of the mononuclear phagocytic system, monocytes, macrophages 
and dendritic cells (DCs) originate from hematopoietic stem cells in the bone marrow and the 
yolk sac (Schulz et al., 2012). The hematopoietic stem cells give rise to myeloid precursors, 
which is followed by the development of macrophage/DC progenitors, which in turn develop into 
monocytes or common DC precursors (Geissmann et al., 2010). Monocytes circulate in the blood 
and enter tissues to replenish the pool of resident macrophages and DCs in steady state or in 
response to inflammation. A variety of cell surface molecules, including F4/80 (Dunkelberger et 
al., 2012), CD11b and CD18 (together forming the macrophage-1 antigen which is also called 
complement receptor 3) (Ehlers, 2000; Schulz et al., 2012) are often used as macrophage 
markers.  
Tissue resident macrophages constantly survey their surroundings for signs of tissue 
damage or infections and maintain tissue homeostasis by removing dead cells and toxic 
materials. In case of infections or tissue injury, macrophages phagocytose and kill bacteria, 
present antigens to T lymphocytes and secrete inflammatory cytokines, free radicals, 
antimicrobial peptides and angiogenic factors. Specialized tissue resident macrophages include 
osteoclasts (bone), alveolar macrophages (lung), Kupffer cells (liver) and microglia (brain) 
(Murray and Wynn, 2011b). 
 
3.2. Microglia: mononuclear phagocytes of the brain 
 
Microglia, which comprise 5 to 20 % of the total glial population of the central nervous 
system (CNS), were first described by Nissl (Nissl, 1899). Microglia were further characterized 
by Santiago Ramon y Cajal and Pio del Rio-Hortega (Ransohoff and Cardona, 2010) who 
proposed the mesodermal origin of this cell type. The myeloid origin of microglia has been 
confirmed using mice deficient in the myeloid-specific transcription factor PU.1, as microglia 
were absent in the CNS of PU.1-/- mice (McKercher et al., 1996). Myeloid progenitors of the yolk 
sac enter the developing brain during early embryogenesis to establish the self-renewing 
microglial population in the brain parenchyma (Ajami et al., 2007; Saijo and Glass, 2011). The 
number of microglia increases in the CNS during pathophysiological conditions as a consequence 
of in situ proliferation of resident cells. In addition, in certain disorders of CNS, the blood-brain 
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barrier becomes disrupted, which process allows blood monocytes to enter the brain and adopt 
microglial-morphology therefore contributing to microgliosis (Flugel et al., 2001).  
Microglia can be found in the CNS in three morphological states, which are ramified, 
activated and amoeboid. In healthy brain, microglia exhibit a ramified phenotype consisting of a 
small soma with extensively branched processes, which continuously monitor their surroundings 
(Ransohoff and Perry, 2009). Once activated by invading pathogens or danger signals, microglia 
adopt a macrophage-like morphology consisting of enlarged soma and shortened processes 
(Ransohoff and Cardona, 2010). Activated microglia secrete proinflammatory cytokines and 
chemokines, have an enhanced ability to phagocytose cells and debris, and increase their antigen 
presentation capacity. Activated microglia contribute to inflammatory processes during 
neurodegenerative diseases, such as multiple sclerosis (Gandhi et al., 2010), Alzheimer’s disease 
(AD) (Amor et al., 2010; Combs, 2009) and Parkinson’s disease (Badoer, 2010; Collins et al., 
2012). Microglia with amoeboid morphology are rounded, phagocytic cells with sparse 
processes, and produce neurotrophic factors (Saijo and Glass, 2011) and participate in synapse 
remodeling (Polazzi and Monti, 2010). Additionally, amoeboid microglia have an important role 
in removal of cell debris and in the reduction of the number of neurons during the development 
of the CNS (Neumann et al., 2009). 
Microglia, similar to other mononuclear phagocytes, recognize molecules that are 
associated with invading pathogens or endogenous danger signals through pathogen recognition 
receptors (PRRs). The unique molecular structures that are recognized by PRRs are called 
pathogen-associated molecular patterns (PAMPs) when they are derived from pathogens and 
damage-associated molecular patterns when they originate endogenously in the tissues. For 
example, microglia express retinoic acid-inducible gene I-like receptors, which recognize 
negative sense RNA viruses, such as vesicular stomatitis virus or Sendai virus (Furr et al., 2008). 
Microglia also express various members of the nucleotide-binding oligomerization domain 
(NOD)-like receptor (NLR) family including NOD2 and NOD-like receptor P3 (NLRP3). It has 
been shown that both intact Streptococcus pneumoniae and the bacterial cell wall product 
muramyl dipeptid activate microglia through NOD2 (Chauhan et al., 2009; Liu et al., 2010). 
NLRP3 expressed by microglia recognizes the AD associated protein amyloid β, which results in 
the production of IL-1β (Halle et al., 2008). Members of the Toll like receptor (TLR) family are 
also expressed by microglia (Carty and Bowie, 2011). There are 10 functional TLRs in humans 
and 12 in mice. TLR activation induces inflammatory responses, which is characterized by, in 
part, the secretion of proinflammatory cytokines and reactive oxygen species. TLR2 recognizes 
cell wall products of Gram-positive bacteria, such as peptidoglycan (PGN) or lipoteichoic acid, 
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while the most important ligand of TLR4 is the lipopolysaccharide (LPS) of Gram-negative 
bacteria (Akira and Takeda, 2004). 
 
3.3. Cytokine production by microglia 
 
Upon activation through PRRs, microglia produce a wide range of proinflammatory 
cytokines. Stimulation of both TLR2 and TLR4 induces tumor necrosis factor (TNF)-α, 
interleukin (IL)-6, IL-12 and IL-1β secretion (Halle et al., 2008; Kielian et al., 2002; Lehnardt et 
al., 2002; Lehnardt et al., 2003; Lin et al., 2010; Liu et al., 2010; Olson and Miller, 2004). TNF-α 
and IL-6 production is also induced by NOD2 stimulation (Chauhan et al., 2009), while NRLP3 
activation results in IL-1β release (Halle et al., 2008). 
IL-6 is considered as a proinflammatory cytokine, although it has become clear recently 
that it also has anti-inflammatory effects in both the CNS and periphery. IL-6 is a major player in 
neuroinflammation which accompanies or induces a wide range of brain disorders and 
neurodegenerative disorders such as traumatic brain injury, infections, multiple sclerosis or AD 
(Amor et al., 2010). It has been proposed that IL-6 can exert both neuroprotective and neurotoxic 
effects, which depend on the concentrations of IL-6 that are present in the various inflammatory 
situations. In lower concentrations, IL-6 produced by microglia or astrocytes increased the 
viability of neurons (Li et al., 2007). In contrast, IL-6 at higher concentrations attenuated neural 
survival in LPS-induced inflammation (Li et al., 2007; Li et al., 2009b). In traumatic brain injury, 
IL-6 has been described to be beneficial since mice overexpressing IL-6 showed accelerated 
healing while IL-6 deficient mice recovered slower than wild-type littermates after brain damage 
(Penkowa et al., 2003; Swartz et al., 2001). IL-6 levels are elevated in stroke patients and IL-6 
appears to contribute to both injury and repair processes after cerebral ischemia (Suzuki et al., 
2009).  
A crucial role for IL-6 has been described in brain disorders featuring chronic 
inflammation. A number of studies have shown that genetic IL-6 deficiency or treatment with 
anti-IL-6 antibody is protective in experimental autoimmune encephalomyelitis (EAE), which is 
an animal model multiple sclerosis, an inflammatory demyelinating disease of the CNS (Eugster 
et al., 1998; Mendel et al., 1998; Serada et al., 2008). IL-6 has also been implicated in another 
neurodegerative disorder, AD, as this condition is accompanied by elevated IL-6 expression in 
the brain (Ershler and Keller, 2000; Tha et al., 2000; Ye and Johnson, 1999), and IL-6-
overexpressing mice display neurodegeneration and cognitive impairment (Heyser et al., 1997).  
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Similarly to IL-6, TNF-α has homeostatic physiological roles besides its proinflammatory 
effects (Clark et al., 2010). TNF-α is present in the healthy, developing brain, and plays an 
important role in reducing the excessive density of neurons, axons and neuronal connections that 
are present in the prenatal brain to normal post-natal levels (Nikolaev et al., 2009; Yamasu et al., 
1989). However, TNF-α concentrations exceeding the normal physiological levels have been 
described in various CNS disorders, including meningitis (Barichello et al., 2009; Moller et al., 
2005), cerebral malaria (John et al., 2008) and Parkinson’s disease (Mogi et al., 1994), where 
they contribute to neurodegenaration. TNF-α also plays important roles in the pathophysiology of 
brain trauma, as its concentrations are elevated in patients with brain injury (Hayakata et al., 
2004) and TNF-α inhibition has been found to be protective in this condition (Ates et al., 2007; 
Shohami et al., 1997). TNF-α is also appreciated as a major player in the pathogenesis of AD, as 
its levels are elevated in the brains of AD patients (Tarkowski et al., 2003) and it contributes to 
neuronal death (Janelsins et al., 2008). In addition, the inhibition of TNF-α has been described to 
be beneficial in mouse AD models providing further evidence for its key role in 
neurodegeneration (McAlpine et al., 2009; Tweedie et al., 2007). 
Since prolonged inflammatory responses in the brain contribute to the pathology of a 
variety of brain disorders, and the regenerative ability of neural tissue is limited, the tight 
regulation of inflammation in the CNS is crucial (Lehnardt, 2010). IL-10 was originally 
described as a T helper 2 (TH2)-type cytokine that inhibits TH1 responses (Fiorentino et al., 
1989). However, it is now clear that IL-10 is a widely expressed anti-inflammatory cytokine that 
is also produced by regulatory T cells and by various innate immune cell types, such as 
microglia, macrophages, and dendritic cells  (Saraiva and O'Garra, 2010). IL-10 influences 
monocyte and macrophage functions by suppressing their inflammatory cytokine production, 
antigen presentation and phagocytosis (Sabat et al., 2010). IL-10 is produced by microglia, 
astrocytes and infiltrating T cells in the brain (Jander et al., 1998; Strle et al., 2001). IL-10 plays 
neuroprotective roles in animal models of numerous CNS disorders, including multiple sclerosis 
(Dai et al., 2012), traumatic brain injury (Knoblach and Faden, 1998), AD (Koronyo-Hamaoui et 
al., 2009), and Parkinson’s disease (Arimoto et al., 2007). In particular, IL-10 exerts its 
protective functions by influencing different cell types in the brain. First, IL-10 influences 
neurons directly by protecting them from glutamate-, nitric oxide (NO)- or hypoxia-induced cell 
death via blocking caspase-3 activity, enhancing the expression of the antiapoptotic proteins, Bcl-
2 and Bcl-xL, and by inhibiting the release of Ca2+ from internal stores to the cytosol (Bachis et 
al., 2001; Silva et al., 2012; Turovskaya et al., 2012; Zhou et al., 2009). Secondly, IL-10 protects 
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brain endothelial cells from bacteremia-induced apoptosis (Londono et al., 2011). Thirdly, IL-10 
exerts neuroprotective effects by inhibiting the inflammatory responses of the brain. 
It has been shown that IL-10 inhibits TNF-α expression by microglia after brain injury, 
the consequence of which is the inhibition of astrocyte reactivity (Balasingam and Yong, 1996). 
IL-10 expressed by microglia also inhibits the expression of proinflammatory mediators and 
neurodegeneration in LPS-injected rat cerebral cortex (Park et al., 2007). Finally, similar to the 
results of in vivo experiments, IL-10 inhibits the LPS-induced release of proinflammatory 
cytokines in microglial cell cultures (Heyen et al., 2000; Kremlev and Palmer, 2005). 
In conclusion, the beneficial or detrimental outcome of neuroinflammation depends on 
the balance of proinflammatory and anti-inflammatory cytokines in the CNS.  
 
3.4. Alternative activation of macrophages 
 
Macrophages can be activated not only by PAMPs but also by different cytokines. The 
TH1 cytokine interferon (IFN)-γ, similar to PAMPs, induces a proinflammatory phenotype in 
macrophages. This population is called classically activated or M1 macrophages. Classically 
activated macrophages produce reactive nitrogen and oxygen species (NO, peroxynitrite, 
hydrogen peroxide, superoxide) and proinflammatory cytokines, such as TNF-  IL-6, and IL-12, 
and they participate in the defense against microbial infections.  
In contrast, alternative macrophage activation occurs in a TH2 cytokine environment, 
arising for example during parasitic disease or wound healing, which imparts immunomodulatory 
and anti-inflammatory rather than proinflammatory properties on macrophages.  The term 
“alternatively activated macrophage” is often more broadly used and includes various anti-
inflammatory macrophage phenotypes induced by various stimuli, including immune complexes, 
IL-10, glucocorticoids, and apoptotic cells, which are collectively denoted M2 (Goerdt and 
Orfanos, 1999; Gough et al., 2001). The most important TH2 cytokines that induce the 
alternatively activated phenotype of macrophages are IL-4 and IL-13.  IL-4 and IL-13 are 
recognized by two types of cell surface receptors. Type I receptors, which are mostly expressed 
on hematopoietic cells, recognize only IL-4 and are composed of IL-4Rα and common cytokine γ 
chain. Type II receptors, which can be activated by both IL-4 and IL-13, are heterodimers of the 
IL-4Rα and IL-13Rα1 chains, and are present also on non-hematopoietic cells (Gordon and 
Martinez, 2010; Sica and Mantovani, 2012). The intracellular signaling pathways emanating 
from these receptors are incompletely characterized and involve members of the Janus-activated 
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kinase (JAK) and signal transducer and activator of transcription (STAT) family, especially 
STAT6 (Nelms et al., 1999), as well as a number of further transcription factors, which include 
CCAAT enhancer binding protein (C/EBP  (Stutz et al., 2003), peroxisome proliferator-
activated receptor γ (Szanto et al., 2010), interferon regulatory factor 4 (El Chartouni et al., 
2010), Krüppel-like factor 4 (Liao et al., 2011), and c-Myc (Pello et al., 2012). 
IL-4 and IL-13 induce a unique, partly overlapping gene expression signature in 
macrophages. One of the hallmark genes induced by IL-4 or IL-13 in macrophages is arginase-1 
(Corraliza et al., 1995; Murray and Wynn, 2011a). Arginase-1 is an enzyme that hydrolyzes L-
arginine to L-ornithine and urea. L-ornithine is a precursor for the formation of proline, which is 
an important constituent of collagen; therefore, arginase-1 is important for extracellular matrix 
deposition and fibrosis (Albina et al., 1990). Arginase-1 in alternatively activated macrophages 
thus contributes to wound healing by facilitating the deposition of extracellular matrix. Arginase-
1 also competes with inducible nitric oxide synthase (iNOS) for the common substrate L-arginine 
and therefore, it is able to regulate IFN-γ-induced NO secretion (Munder, 2009; Munder et al., 
1998).  
Alternatively activated macrophages upregulate a number of further genes that are 
involved in extracellular matrix turnover, and these genes include tissue inhibitor of 
metalloproteinase (TIMP)-1 and several matrix metalloproteinases. In addition to its effects on 
extracellular matrix turnover, TIMP-1 has complex effects on cell growth and mutations in the 
matrix metalloproteinases-inhibitory domain of TIMP-1 fail to abrogate the effects of TIMP-1 on 
cell growth and survival (Moore and Crocker, 2012; Moore et al., 2011). 
Macrophage galactose-type C-type lectin (mgl)-1 is a member of the family of C-type 
lectin receptors and is expressed on immature dendritic cells and macrophages (van Vliet et al., 
2008). The mgl-1 binds glycoproteins expressed by helminthes but it is also able to recognize 
tumor glycoproteins (Aarnoudse et al., 2006). Recent findings showing that mgl-1 expression on 
macrophages is induced in vivo by parasitic infection and in vitro by IL-4/IL-13, implicated mgl-
1 as a marker of alternative activation (Raes et al., 2005). 
Resistin-like molecule-α (RELM-α) belongs to a cysteine-rich secreted protein family and 
it is secreted by macrophages in response to IL-4 or IL-13 (Raes et al., 2002a; Raes et al., 
2002b). RELM-α expression is elevated in lung inflammation induced by bleomycin (Liu et al., 




Additional proteins that are appreciated as markers of alternative activation are the 
chitinase-like proteins Ym1 and Ym2 (Chang et al., 2001), which are upregulated in 
macrophages and epithelial cells in response to IL-4 or the chitin of invading parasites (Gordon, 
2003; Raes et al., 2002a). 
 
3.5. Adenosine is an extracellular signaling molecule 
 
Adenosine is a purine nucleoside, which is an essential component of intracellular 
metabolic processes and is a precursor of both nucleic acid and adenosine 5’-triphosphate (ATP) 
synthesis. Adenosine can be released into the extracellular space in response to both metabolic 
disturbances and other types of insults, which include inflammation, physical damage, and 
apoptosis (Hasko and Pacher, 2012). Drury and Szent-Györgyi discovered that extracellularly 
released adenosine is a signaling molecule that regulates heart rate, coronary vascular tone, and 
intestinal physiology (Drury, 1929). Since the discovery of the signaling role of adenosine, it has 
become clear that extracellular adenosine has wide-ranging regulatory effects in all organs and 
tissues (Hasko and Cronstein, 2004). 
The release of adenosine can occur via two mechanisms: (a) via direct release through 
cell membrane integral adenosine/nucleoside transporters and (b) as constituent of adenine 
nucleotides, such as ATP and ADP, which can be externalized by a variety of mechanisms, 
including membrane damage, through connexin/pannexin and other channels, and via protein or 
hormone-transporting vesicles (Hasko and Pacher, 2012). Once ATP and ADP are released, the 
phosphate groups of extracellular ATP and ADP are sequentially cleaved off, first by nucleoside 
triphosphate diphosphorylases (NTPDases, including CD39) and then by 5’-ectonucleotidase 
(Ecto5’Ntase, CD73) (Bours et al., 2006; Deaglio and Robson, 2011). In addition to host cells, 
pathogens such as Staphylococcus aureus (Thammavongsa et al., 2009), enteropathogenic 
Escherichia coli (Crane et al., 2002), and Trichomonas vaginalis (Tasca et al., 2003) are 
equipped with ectonucleotidases, and excessive adenosine generation by these ectonucleotidases 
contributes to the subversion of the host immune system and propagation of the pathogens 
(Hasko and Pacher, 2012). Adenosine has a short half-life in the extracellular space because it is 
either rapidly degraded extracellularly to inosine by adenosine deaminase or is rephosphorylated 





3.6. Adenosine receptors (ARs) 
 
The cellular effects of adenosine are mediated by ARs, which are members of the G 
protein-coupled family of receptors. The four subtypes of ARs are the A1, A2A, A2B and A3AR 
(Fredholm et al., 2001). The A1AR and A3AR are coupled to Gi proteins, which inhibit the 
enzyme adenylyl cyclase thereby decreasing intracellular cyclic AMP (cAMP) concentrations. 
However, they activate other intracellular signal transducers, such as protein kinase C, 
phosphoinositide kinase (PI3K), Akt, and a member of the mitogen activated protein kinase 
(MAPK) family, extracellular signal regulated kinase (ERK) 1/2 (also called p42/44) (Schulte 
and Fredholm, 2003b). Additionally, A3AR is also able to signal through the phospholipase C 
(PLC) pathway and intracellular Ca2+ via Gq proteins (Gessi et al., 2008). The A2AAR and 
A2BAR couple to Gs proteins which activate adenylyl cyclase followed by the increase of 
intracellular cAMP concentration (Fredholm et al., 2001). Increased cAMP levels activate the 
protein kinase A (PKA) pathway and consequently the transcription factor cAMP responsive 
element binding protein (CREB). cAMP signals also through exchange proteins directly activated 
by cAMP (EPAC) (Breckler et al., 2011). Additionally, A2AAR has been described to activate G 
protein-independent pathways, which involve G protein-coupled receptor kinases and β-arrestins 
(Zezula and Freissmuth, 2008). The A2BAR can also couple to Gq, as well as other pathways such 
as MAPKs and PI3K (Schulte and Fredholm, 2003b). 
 
3.7. Immunomodulatory effects of adenosine 
 
The concept of adenosine as an immunomodulatory signaling molecule was first 
established  with the discovery of the inhibitory effect of adenosine on superoxide generation by 
neutrophils (Cronstein et al., 1983). It has become clear since then that adenosine influences a 
wide range of immune functions of a variety of cell types, including mononuclear phagocytes, 
lymphocytes, natural killer cells, and mast cells (Bours et al., 2006; Hasko et al., 2008). 
Microglial functions regulated by ARs include proliferation, migration and secretion of 
proinflammatory mediators and neurotrophic factors. In particular, adenosine can both inhibit 
and induce proliferation in microglia depending on factors such as AR subtype expression, the 
activation state of the microglia, and the environment. Adenosine also regulates the production of 
proinflammatory mediators by microglia, and there are reports of both positive and negative 
regulatory effects. The stimulation of microglial A2AARs has been shown to inhibit LPS-induced 
secretion of TNF-α and IL-12 (van der Putten et al., 2009), but induces the expression of 
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cyclooxygenase-2 and the release of NO (Fiebich et al., 1996; Saura et al., 2005). Another study 
identified the A3AR in mediating the inhibiting effect of adenosine on LPS-induced TNF-α 
production (Lee et al., 2006). Thus, a substantial amount of data suggests that adenosine exerts 
complex regulatory functions on microglia. 
Adenosine also decreases the expression of proinflammatory cytokines, such TNF-α and 
IL-12 by classically activated peripheral monocytes and macrophages (Hasko et al., 2000; Hasko 
et al., 1996). The inhibitory effect of adenosine on TNF-α production is mediated primarily by 
A2AARs (Buenestado et al., 2010; Kreckler et al., 2006; Ryzhov et al., 2008b; Zhang et al., 
2005); however, recently published data show that A2BARs can also contribute to the effect 
(Belikoff et al., 2011; Chen et al., 2009). Adenosine also inhibits the LPS-induced production of 
the chemokine, macrophage inflammatory protein-1α by macrophages, which occurs through the 
A3AR (Szabo et al., 1998). LPS-induced NO production, IFN-γ-induced iNOS expression, and 
the release of reactive oxygen species are negatively regulated by adenosine (Barnholt et al., 
2009; Hasko et al., 1996) through A3ARs (Broussas et al., 1999; Leonard et al., 1987; Thiele et 
al., 2004). In addition to the inhibition of proinflammatory functions of macrophages, adenosine 
augments the production of IL-10. The effect is mediated by A2AAR in peritoneal macrophages 
activated by heat killed bacteria (Csoka et al., 2007) and by A2BAR in RAW 264.7 macrophages 
activated with LPS (Nemeth et al., 2005). Adenosine has also been shown to be involved in the 
regulation of angiogenesis by macrophages (Adair, 2005). Particularly, A2AAR stimulation in 
macrophages augments the production of vascular endothelial growth factor (VEGF) which is an 
important component of angiogenesis and wound healing (Ernens et al., 2010; Leibovich et al., 
2002; Pinhal-Enfield et al., 2003). 
Thus, adenosine regulates virtually all important functions of mononuclear phagocytes 
which makes the ARs possible targets for the therapy of various pathological conditions affecting 
the immune system (Hasko et al., 2008). 
 
3.8. Aims of the study 
 
The last 2 to 3 decades have seen a dramatic increase in our understanding of the role of 
ARs in regulating the function of mononuclear phagocytes. However, several gaps remained. For 
example, while the role of ARs in regulating proinflammatory cytokine production by microglia 
had been addressed prior to our studies, the effect of adenosine on IL-10 production by microglia 
had not been studied. In addition, prior to our studies, the effect of adenosine had only been 
studied in conjunction with classically activated macrophages and the role of adenosine in 
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regulating alternative macrophage activation had not been explored. To begin to fill these gaps, 
we sought to address the following aims: 
1. Determine the effect of adenosine on IL-10 production by microglia activated with TLR 
ligands. Compare the effect of adenosine on IL-10 production with its effect on IL-6, IL-12 
and TNF-α production. 
2. Identify the AR subtype mediating the effect of adenosine on IL-10 production by 
microglia 
3. Examine the intracellular signaling pathways that mediate the effect of adenosine on IL-
10 production by microglia 
4. Delineate the effect of adenosine on IL-4 or IL-13-induced alternative macrophage 
activation  
5. Elucidate the AR subtypes responsible for the effect of adenosine on alternative 
macrophage activation  
6. Determine the intracellular signaling pathways that mediate the effect of adenosine on 




4. Materials and methods 
 
4.1. Drugs and reagents 
 
Adenosine, the selective A1AR agonist 2-chloro-N6-cyclopentyladenosine (CCPA), A2AAR 
agonist 4-[2-[[6-amino-9-(N-ethyl-β-D-ribofuranuronamidosyl)-9H-purin-2-yl]amino]ethyl] 
benzenepropanoic acid (CGS21680), A3AR agonists 1-deoxy-1-[6-[[(3-
iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-β-D-ribofuranuronamide (IB-MECA) and 
1-[2-Chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-β-D-
ribofuranuronamide (Cl-IB-MECA), nonselective AR agonist 1-(6-Amino-9H-purin-9-yl)-1-
deoxy-N-ethyl-β-D-ribofuranuronamide (NECA), the selective A1AR antagonist 8-cyclopentyl-
1,3-dipropylxanthine (DPCPX), A2AAR antagonist 4-(2-[7-amino-2-(2-furyl)[1.2.4]triazolo[2.3-
a][1.3.5]-triazin-5-ylamino] ethyl) phenol (ZM241385), A2BAR antagonist N-(4-cyanophenyl)-2-
[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide (MRS1754), 
A2BAR antagonist 8-[4-[4-(4-chlorobenzyl)piperazide-1-sulfonyl)phenyl]]-1-propylxanthine 
(PSB0778), A3AR antagonist 3-propyl-6-ethyl-5-[(ethylthio) carbonyl]-2 phenyl-4-propyl-3-
pyridine carboxylate (MRS1523), β-adrenoceptor agonist isoproterenol, and prostaglandin E2 
(PGE2) were purchased from Tocris Cookson (Ellisville, MO). The p38 MAPK pathway inhibitor 
SB203580 and p42/44 MAPK pathway inhibitor PD98059 were purchased from Calbiochem 
(San Diego, CA). The c-Jun N-terminal kinase (JNK) inhibitor anthra[1-9-cd]pyrazol-6(2H)-one 
(SP600125), the PKA inhibitor N-[2-[[3-(4-bromophenyl)-2-propenyl]amino]ethyl]-5-
isoquinolinesulfonamide dihydrochloride (H89), PI3K inhibitor 2-(4-morpholinyl)-8-phenyl-4H-
1-benzopyran-4-one hydrochloride (LY294002) and PLC inhibitor 1-[6-[[(17β)-3-methoxyestra-
1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione (U73122) were purchased from Tocris. 
PGN and LPS were purchased from Sigma-Aldrich (St. Louis, MO). Stock solutions of the 
various agonists and protein kinase inhibitors were prepared using dimethylsulphoxide. Murine 
recombinant IL-4 and IL-13 were from PeproTech (Rocky Hill, NJ, USA). Stock solutions of 





4.2. Experimental animals 
 
Male C57BL/6 mice and male TLR4 KO (C57BL/10ScNJ) and WT (C57BL/10ScSnJ) 
mice were purchased from Charles River Laboratories (Isaszeg, Hungary) or from the Jackson 
Laboratory (Bar Harbor, ME, USA). All mice were maintained in accordance with the 
recommendations of the "Guide for the Care and Use of Laboratory Animals", and the 
experiments were approved by the Animal Care Committee of the Hungarian Academy of 
Sciences and New Jersey Medical School Animal Care Committee. A2B receptor KO mice on the 
C57BL/6J genetic background were acquired from Deltagen (San Mateo, CA, USA) and were 
bred as described previously (Csoka et al., 2010; Csoka et al., 2007). A2A receptor KO mice on 
the C57BL/6J genetic background were kindly provided by Dr. Joel Linden (La Jolla Institute for 
Allergy and Immunology, La Jolla, CA, USA).  
 
4.3. Cell cultures 
 
BV-2 is a murine microglial cell line immortalized by retroviral transduction with v-raf/v-
myc genes (Blasi et al., 1990). BV-2 cells were grown in Dulbecco’s Modified Eagle Medium 
(DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) (Sigma-
Aldrich), 50 U/mL penicillin, and 50 g/mL streptomycin (Invitrogen) in a humidified atmosphere 
of 95% air and 5% CO2. C/EBP -deficient and control immortalized macrophages (kind gifts 
from Dr. Jorge A. Albina, Rhode Island Hospital and Brown Medical School, Providence, RI, 
USA) (Albina et al., 2005; Gorgoni et al., 2002) and RAW 264.7 macrophages (ATCC, 
Manassas, VA, USA) were grown in DMEM supplemented with 10% FBS, 50 U/ml penicillin, 
50 μg/ml streptomycin, and 1.5 mg/ml sodium bicarbonate in a humidified atmosphere of 95% 
air and 5% CO2. 
Primary microglia were obtained from 1- to 3-day-old C57BL/6J mice. Cerebral cortices 
were dissected, carefully stripped of their meninges, and digested with 0.05% trypsin (Sigma-
Aldrich) and 0.6 mg/ml DNase (Sigma-Aldrich) dissolved in 2 ml of phosphate buffered saline 
(PBS) for 10 min. Trypsinization was stopped by adding an equal volume of DMEM. The cells 
were then placed in cell culture flasks previously treated with poly-lysine (Sigma-Aldrich) and 
after an overnight incubation, non-adherent cells were removed by washing with culture medium. 
The remaining adherent mixed astrocyte-microglia culture was then incubated at 37°C in a 
humidified atmosphere of 95% air and 5% CO2, and the medium replaced every 3 d until the 
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cells reached confluence (14-16 d). Confluent cultures were trypsinized and microglia were 
separated using CD11b MicroBeads from Miltenyi Biotec (Auburn, CA). 
To obtain peritoneal macrophages, mice were injected intraperitoneally with 3 ml of 
sterile thioglycollate (TG) broth (4% w/v). After 4 d, the mice were sacrificed and peritoneal 
exudate cells were harvested using 10 ml of DMEM. Cells were centrifuged at 300 x g for 10 
min at 4°C, washed twice with DMEM, and re-suspended in DMEM containing 10 % FBS, 50 
U/ml penicillin, 50 g/ml streptomycin, and 1.5 mg/ml sodium bicarbonate. Cells were seeded 
into tissue culture plates and incubated at 37°C in a humidified incubator for 5 h, to allow the 
cells to adhere. Non-adherent cells were then removed by washing with serum-free DMEM, and 
the cells were re-fed with DMEM containing 10 % FBS. After 18 h of incubation, various test 
compounds were added to the macrophages. 
 
4.4. Enzyme-linked immunosorbent assay (ELISA) for determining cytokine production 
 
BV-2 cells, primary microglial cells, RAW 264.7 macrophages or peritoneal 
macrophages were placed in the wells of 96-well plates (105 cells/well). After an overnight 
incubation, supernatants were replaced with serum-free cell culture medium and the cells were 
incubated for 2 h. The cells were then treated with adenosine or various AR agonists, PGN, LPS, 
IL-4 or IL-13 for 2, 4, 8, 12 or 24 hours after which periods the supernatants were frozen and 
stored. AR antagonists or protein kinase inhibitors were administered 30 min prior to treatment 
with adenosine or NECA. IL-10, TNF-α, IL-6, IL-12 and TIMP-1 levels in cell culture 
supernatants were determined using ELISA Duoset kits (R&D Systems, Minneapolis, MN). 
 
4.5. RNA extraction, cDNA synthesis, and real-time polymerase chain reaction (PCR) 
 
Total RNA was prepared from peritoneal macrophages, BV-2 or RAW 264.7 cells using 
Trizol reagent according to the manufacturer’s protocol (Invitrogen) or from primary microglia 
using RNeasy Mini Kit according the manufacturer’s protocol (Qiagen, Valencia, Ca), and 
reverse-transcribed using High Capacity cDNA Reverse Transcription kit (Applied Biosystems, 
Foster City, CA). For detection of IL-10, AR, arginase-1, TIMP-1, and mgl-1 mRNA, a real-time 
PCR commercial kit (Applied Biosystems) was used, and all data were normalized to constitutive 
rRNA values (18S). The primers used are listed in Table 1. The Applied Biosystems 7700 
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sequence detector was used for amplification of cDNA, and quantitation of differences between 





















4.6. Transient transfection of BV-2 cells with IL-10 promoter-luciferase and pCRE 
luciferase constructs and luciferase assay 
 
BV-2 cells were transiently transfected using Polyfect transfection reagent (Qiagen). For 
transfection, cells were plated at 2.5 x 105 per ml density overnight, and at plating, each well of a 
24-well plate contained 0.5 ml of cell suspension. The following day, the cells were transfected 
with 0.4 μg per well of IL-10 reporter plasmids (kind gifts from Stephen T. Smale, University of 
California, Los Angeles, School of Medicine, Los Angeles, CA) and CREB reporter plasmid 
(pCRE) (Stratagene, La Jolla, CA). All transfections were performed at 37°C overnight, after 
which procedure the cells were washed with DMEM and treated with 10 μM NECA and/or 20 
μg/ml PGN for 8 h. For reporter assays, whole-cell extracts were prepared using 80 μl of 1x 
Table 1: Oligonucleotide sequences for real-time PCR 
 
A1AR:   forward: 5’-GTGATTTGGGCTGTGAAGGT-3’ 
  reverse:  5’-CAAGGGAGAGAATCCAGCAG-3’ 
A2AAR:   forward: 5’-AGCAGTTGATGATGTGCAGG-3’ 
  reverse: 5’-CACGCAGAGTTCCATCTTCA-3’ 
A2BAR:   forward: 5’-TGGCGCTGGAGCTGGTTA-3’ 
  reverse: 5’-GCAAAGGGGATGGCGAAG-3’ 
A3AR:   forward: 5’-GACTGGCTTCAGAGAGACGC-3’ 
  reverse: 5’-AGGGTTCATCATGGAGTTCG-3’ 
IL-10:   forward: 5’-AAGGAGTTGTTTCCGTTA-3’ 
  reverse: 5’-AAGGGTTACTTGGGTTGC-3’ 
arginase-1: forward: 5’-CAGAAGAATGGAAGAGTCAG-3’ 
  reverse: 5’ CAGATATGCAGGGAGTCACC-3’ 
TIMP-1: forward: 5’- TCCTCTTGTTGCTATCACTGATAGCTT-3’ 
  reverse: 5’- CGCTGGTATAAGGTGGTCTCGTT-3’ 
mgl-1:  forward:5’ - CCTCCAGAACTCAAGGATGC - 3’ 
  reverse: 5’- GATCCAATCACGGAGACGAC - 3’ 
18S:  forward: 5’-GTAACCCGTTGAACCCCATT-3’ 
  reverse:  5’-CCATCCAATCGGTAGTAGCG-3’ 
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passive lysis buffer from each well (Promega, Madison, WI). Luciferase activity was determined 
using 20 μl of cell extract with Dual-Luciferase Reporter Assay System (Promega). 
 
4.7. Transient transfection of RAW 264.7 cells with arginase-1 promoter-luciferase 
construct, C/EBP luciferase construct, and luciferase assay 
 
RAW 264.7 cells were transiently transfected using FUGENE 6.0 transfection reagent 
(Roche, Indianapolis, IN, USA). For transfection, 5 x 105 per ml cells were seeded in a 24-well 
plate. The next day, the cells were transfected with a mixture of arginase-1 or C/EBP reporter 
plasmid (Stratagene, Santa Clara, CA, USA) and FUGENE reagent, where the final concentration 
of the plasmids was 2 μg per ml and that of FUGENE was 10 μl per ml. The arginase-1 luciferase 
reporter construct was created by cloning -3810/-31 (relative to the transcription start site) 
promoter fragment into the pGL3-basic vector (Promega, Madison, WI, USA) (Pauleau et al., 
2004). All transfections were performed at 37°C overnight, and the following day the cells were 
washed with medium and treated with IL-4 and adenosine for 4 or 8 h. For reporter assays, 
whole-cell extracts were prepared using 80 μl of 1x passive lysis buffer (Promega, Madison, WI, 
USA). Luciferase activity was determined using 20 μl of cell extract. 
 
4.8. Whole cell protein isolation and Western blotting 
 
Peritoneal macrophages, BV-2 cells or RAW 264.7 cells placed in wells of 6-well plates 
were treated with adenosine or NECA and/or PGN or IL-4. Cells were washed with PBS and 
pelleted at 800 x g for 5 min at 4°C. The pellet was resuspended in radioimmunprecipitation 
assay lysis buffer (0.05 M TRIS-HCl pH 6.8, 0.25% Na-deoxycholate, 0.15 M NaCl, 1 mM 
EDTA pH 7.4, 1 mM Na3VO4, 1 mM NaF, 1% NP-40, 1 mM PMSF, 100x diluted Proteinase 
inhibitor cocktail mix) and incubated on ice for 15 min. The lysates were centrifuged at 15,000 x 
g for 15 min at 4°C, and the supernatant was recovered. Protein concentrations were determined 
using Bio-Rad protein assay (Bio-Rad, Hercules, CA). Whole cell lysates containing 30 g of 
protein were separated on a 10% Tris-glycine gel (Invitrogen). After electrophoresis, the gel was 
electroblotted in 1X Transfer buffer (Invitrogen) containing 20% methanol onto a nitrocellulose 
membrane (Invitrogen). The membranes were probed with monoclonal rabbit anti-mouse 
primary antibodies raised against p38, phospho-p38, p42/44, phospho-p42/44, phospho-JNK, 
Akt, phospho-Akt, CREB, phospho-janus kinase (JAK) 1 and 3, phospho-Shc (Cell Signaling 
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Technology, Danvers, MA), arginase-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or 
phospho-STAT-6 (Abcam, Cambridge, MA, USA). Thereafter, the membranes were incubated 
with a secondary horseradish peroxidase (HRP)-conjugated goat anti-rabbit antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA). HRP-conjugated polyclonal goat anti- -actin antibody to assess 
equal loading was used from Santa Cruz Biotechnology. Bands were detected using 
Chemiluminescent HRP Detection Reagent (Denville Scientific, South Plainfield, NJ). X-ray 
films were exposed for 1-15 min. 
 
4.9. Silencing CREB using lentivirally-delivered shRNA 
 
BV-2 or RAW 264.7 cells, placed in 12-well plates (5 X 104 cells/well), were transduced 
with Mission Lentiviral particles containing CREB-specific shRNA or non-targeting shRNA 
(Sigma-Aldrich) in the presence of 8 μg/ml hexadimethrine bromide. The sequences of the 
shRNA oligos are shown in Table 2. The multiplicity of infection was 4 for each transduction. 
After overnight incubation, the supernatants were replaced with complete cell culture medium 
and the cells were incubated for a further 48 h. Then, to select the transduced cells, 2 μg/ml 
puromycin was added to the cultures. The cells were cultured in the presence of puromycin for an 
additional 48 h. The surviving cells considered as stable shRNA expressing cell lines were 
transferred to a cell culture flask and cultured in the presence of puromycin as described above. 
The efficiency of silencing was tested by Western blotting using CREB specific monoclonal 













Table 2: shRNA sequences for CREB down-regulation 
 
#32 ( Region: coding sequence): 
5’-CCGGAGCAAGAGAATGTCGTAGAAACTCGAGTTTCTACGACATTCTCTTGCTTTTTTG-3’ 
 







4.10. Chromatin immunoprecipitation (ChIP) 
 
ChIP was performed using a ChIP assay kit from Millipore (Billerica, MA) according to 
the manufacturer’s protocol. Phospho-CREB-specific monoclonal antibody and normal 
immunoglobulin G (IgG) antibody provided with the kit for control were used. PCR reaction was 
performed using DNA purified from ChIP samples using primers specific for the region between 
-376 and -158 relative to the transcription start site of the of IL-10 gene. Primers were designed 
by using Primer3 software and synthesized by the Molecular Research Facility of UMDNJ. The 
sequences of the primers used were: AGCCCATTTATCCACGTCAT – pIL10 forward; 
TTGTATTTCCTGAGGCAGACAG – pIL10 reverse. The PCR was performed using Taq PCR 
Polymerase kit from Qiagen. 
 
4.11. Determination of arginase activity from macrophage cell extracts 
 
RAW 264.7 cells, murine peritoneal macrophages or C/EBP -deficient and control 
immortalized macrophages in 96-well plates (2 x 106 per ml) were treated with PSB0778 or 
SB203580 and then either with adenosine or various AR agonists followed by the addition of IL-
4 or IL-13. At the end of the incubation period, cell extracts were prepared from 2 x 105 cells in 
50 l of 10 mM Tris-HCl (pH 7.4) containing 0.4% Triton X-100. After centrifugation at 2,500 x 
g for 30 min, arginase activity in the supernatants of cell extracts was determined using a 
commercially available arginase assay kit (QuantiChromTM Arginase assay Kit; Bioassay 
Systems, Hayward, CA, USA). The measured arginase activity was normalized to 2 x 105 cells. 
 
4.12. Statistical analysis 
 
Values in the figures are expressed as mean plus or minus the standard error of the mean 
(SEM) of the indicated number of observations. Statistical analyses of the data were performed 








5.1. Adenosine augments IL-10 and inhibits IL-6, TNF-α and IL-12 production by 
activated microglia 
 
To examine the effect of adenosine on pro- and anti-inflammatory cytokine production by 
activated microglial cells, we first treated primary microglia with adenosine and PGN. We then 
determined IL-10, IL-6, and TNF-α concentrations in the supernatants after 24 h of treatment. 
The results show that PGN enhanced dramatically IL-10, IL-6 and TNF-α production by primary 
microglia (Figure 1). Adenosine treatment augmented the PGN-induced secretion of IL-10 






Next, we investigated the effect of adenosine on cytokine production by BV-2 cells 
stimulated with PGN or LPS. The combination of adenosine and PGN synergistically induced IL-
10 production, while neither adenosine nor PGN alone was able to elicit IL-10 release by BV-2 
cells (Figure 2A). We found that adenosine synergistically induced IL-10 production in LPS-
activated BV-2 cells, as well (Figure 2A). PGN or LPS induced IL-6 (Figure 2B and C), TNF-
Figure 2D), and IL-12 (Figure 2E) production by BV-2 cells. Adenosine inhibited the PGN- or 
LPS-induced production of all three cytokines (Figures 2B-E). 
 
 
Figure 1: Adenosine augments IL-10 and inhibits IL-6 and TNF-α production by PGN-treated 
microglia. Cells were treated with 100 μM adenosine immediately followed by treatment with 20 
μg/ml PGN for 24 h. Cytokine concentrations were determined from supernatants using ELISA. 










5.2. The effect of adenosine on IL-10 production by BV-2 cells is A2BAR-dependent 
 
To determine which AR is responsible for the IL-10-increasing effect of adenosine, we 
first treated BV-2 cells with increasing concentration of various AR agonists immediately 
followed by treatment with PGN or LPS for 24 hours. Our results showed that NECA was the 
most potent IL-10 enhancer in BV-2 cells (Figure 3). These results suggest the primary role of 
A2BAR in mediating the IL-10 enhancing effect of adenosine, because if NECA is the most 
potent agonist in a system, it indicates a predominant role for A2B receptors (Feoktistov and 
Biaggioni, 1993; Feoktistov and Biaggioni, 1998). 
  
Figure 2: Adenosine augments IL-10 and inhibits IL-6, TNF-α and IL-12 production by BV-2 
cells. Cells were treated with 100 μM adenosine immediately followed by treatment with 20 μg/ml 
PGN or 10 μg/ml LPS for 24 h. Cytokine concentrations were determined from supernatants using 
ELISA. Results are representative of 3 independent experiments. Data are shown as mean ± SEM 










In the next step, we tested which antagonist could reverse the increasing effect of NECA. 
We found that MRS1754 inhibited the stimulatory effect of NECA on IL-10 production by PGN- 
(Figure 4A) or LPS-treated (Figure 4B) cells. However, DPCPX, ZM241385, and MRS1523 
failed to reverse the effect of NECA. Thus, these data confirm that adenosine augments IL-10 





Figure 3. NECA is the most potent AR agonist in enhancing IL-10 production by PGN- or 
LPS-treated BV-2 cells. Cells were treated with increasing concentrations of CCPA, CGS21680, 
NECA or IB-MECA followed by treatment with 20 μg/ml PGN (A) or 10 μg/ml LPS (B) for 24 h. 
IL-10 concentrations were determined from supernatants using ELISA. Results are representative of 
3 independent experiments. Data are mean ± SEM (n=4); *p<0.05 vs. PGN, **p<0.01 vs. PGN, 
***p<0.001 vs. PGN (A) or LPS (B). 
Figure 4. The A2BAR antagonist MRS1754 inhibits IL-10 production by NECA and PGN or 
LPS-treated cells. BV-2 cells were treated with various AR antagonists 30 min before treatment 
with 10 μM NECA and 20 μg/ml PGN (A) or 10 μg/ml LPS (B). IL-10 concentrations were 
determined from supernatants using ELISA. Results are representative of 3 independent 
experiments. Data are shown as % of NECA+PGN (A) or NECA+LPS treatment (B) (mean ± SEM; 
n=4); ***p<0.001 vs. vehicle (NECA+PGN (A) or LPS (B)). 
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We next studied the level of expression of AR mRNA in unstimulated BV-2 cells and 
primary microglia using real-time PCR. We found that the levels of A2BAR and A3AR were 
highest in BV-2 cells, whereas low levels of A1AR and A2AAR were detected (Figure 5A). In 
primary microglia, the A2BAR was the dominantly expressed receptor, and lower levels of A1AR, 
A3AR, and A2AAR were detected (Figure 5B). We then investigated the effect of PGN and LPS 
on AR mRNA expression. In BV-2 cells, LPS augmented the mRNA level of all ARs with the 
exception of the A3AR. In contrast, PGN augmented A2BAR mRNA levels and decreased the 
levels of the A3AR (Figure 5A). In primary microglia, both PGN and LPS treatment increased 









5.3. AR activation augments IL-10 mRNA accumulation in a CREB-dependent manner 
 
To determine whether the stimulatory effect of AR activation on IL-10 production is 
transcriptional, we measured IL-10 mRNA levels following treatment with NECA and/or PGN. 
Our results showed that NECA augmented IL-10 mRNA levels in BV-2 cells exposed to PGN 
(Figure 6). This effect was completely abolished in cells pre-treated with the transcription 
inhibitor actinomycin D (Figure 6). These data suggest that NECA and PGN augment IL-10 
production by a transcriptional mechanism. 
Figure 5. Expression of AR mRNA in microglia.  BV-2 cells (A) or primary microglia (B) were 
treated with 20 μg/ml PGN or 10 μg/ml LPS for 4 h and then RNA was isolated from the cells. AR 
mRNA levels were determined using real-time PCR with primers specific for the particular ARs. 
Results were normalized to 18S mRNA levels and are representative of 3 independent experiments. 
Data are shown as mean ± SEM (n=4); ***p<0.001 vs. A1 vehicle. &&p<0.01 vs. A2A vehicle, 










To further characterize the mechanism by which NECA increased IL-10 mRNA 
expression, we assessed the effect of NECA on IL-10 promoter activity using luciferase reporter 
plasmids in which luciferase expression was driven by the IL-10 promoter. In addition, we used 
promoter mutants, which contained successive deletions from the 5’ end of the IL-10 promoter 
(Brightbill et al., 2000). BV-2 cells transfected with the reporter plasmids were then treated with 
NECA and/or PGN and promoter activity was indicated by luciferase activity in cell lysates. 
NECA augmented luciferase activity in cells transfected with the full promoter (-1538/+64 
relative to the transcription start site), which indicated that NECA increases IL-10 transcription 
by upregulating IL-10 promoter activity. Next, we attempted to pinpoint the cis-regulatory region 
of the IL-10 promoter that mediated the effect of NECA. We found that NECA augmented 
luciferase activity in cells transfected with mutant promoter constructs containing deletions 
between -1538 and -376 bp relative to the transcription start site (Figure 7A); however, NECA 
failed to augment luciferase activity in cells transfected with constructs with deletions between -
346 and -78 bp (Figure 7A). Using the Searching Transcription Factor Binding Sites tool 
(http://www.cbrc.jp/research/db/TFSEARCH.html), we found binding site for the transcription 
factor CREB in this region (Figure 7B). We then transfected cells with a CREB-reporter 
construct in which luciferase activity was driven by tandem CREB-binding sequences (pCRE). 
NECA augmented luciferase activity in cells transfected with pCRE but failed to do so in cells 
Figure 6. NECA augments IL-10 mRNA levels in PGN-treated cells. BV-2 cells were treated 
with 5 μg/ml actinomycin D or its vehicle 2 hours before treating with 10 μM NECA and/or 20 
μg/ml PGN for a further 6 h. Total RNA was isolated from the cells and reverse transcribed to 
cDNA. IL-10 mRNA levels were determined by real-time PCR using primers specific for IL-10. 
Results were normalized to 18S mRNA levels and are shown as fold increase relative to untreated 
samples. Data are shown as mean ± SEM (n=4); ***p<0.001 vs. PGN, ###p<0.001 vs. NECA+PGN. 
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We next used ChIP assay to further analyze the role of CREB in mediating the 
stimulatory effect of NECA on IL-10 production. Immunoprecipitation with antibodies against 
phosphorylated CREB followed by PCR with primers specific for the region between -376 and -
158 of the IL-10 promoter showed that CREB phosphorylation occurs at this site after combined 
treatment with NECA and PGN (Figure 8A).  
 
Figure 7. NECA augments IL-10 promoter activity. (A) BV-2 cells were transfected with IL-10 
promoter-luciferase constructs containing successive deletions. Transfected cells were treated with 
10 μM NECA and 20 μg/ml PGN for 8 h and luciferase activity was determined from the cell 
lysates. (B) Representation of the sequence of the region between -376 and -158 bp relative to the 
transcription start site of the IL-10 gene, which contains a CREB-binding site. (C) Cells were 
transfected with a reporter plasmid in which luciferase activity is driven by CREB-binding sites 
(pCRE) or control vector (pCIS). Transfected cells were treated with 10 μM NECA and/or 20 μg/ml 
PGN for 8 h and luciferase activity was determined from cell lysates. Luciferase values were 
normalized to protein concentration. Results are representative of 3 independent experiments. Data 















We then used a gene silencing approach to determine whether CREB was required for the 
stimulatory effect of NECA on IL-10 production. We transduced BV-2 cells with lentiviral 
particles containing non-targeting shRNA or shRNA specific for CREB. Transducing the cells 
with CREB-specific shRNA resulted in a strong downregulation of CREB expression, as 
confirmed using Western blotting (Figure 8B). Then, we treated non-targeting or CREB-specific 
shRNA-expressing BV-2 cells with NECA and/or PGN and determined IL-10 production. The 
results showed that the stimulatory effect of NECA on PGN-induced IL-10 production was 
dramatically diminished in cells expressing CREB-specific shRNA as compared to cells 
Figure 8. The stimulatory effect of NECA on IL-10 production is CREB-dependent. (A) BV-2 
cells were treated with 10 μM NECA and/or 20 μg/ml PGN for 30 min and ChIP assay was performed 
on cell extracts using phospho-CREB–specific and control Abs. PCR reaction was then performed 
using the DNA purified from ChIP samples using primers specific for the IL-10 promoter. PCR 
products were separated on a 3% agarose gel stained with ethidium bromide and visualized under UV 
light. (B) BV-2 cells were transduced with lentiviral vectors containing CREB-specific or 
nontargeting (NT) shRNA. Protein was then isolated from transduced and untransduced BV-2 cells, 
and CREB expression was tested by Western blotting using Abs specific for CREB or for actin as 
loading control. (C) BV-2 cells transduced with NT or CREB-specific shRNA were treated with 10 
μM NECA and 20 μg/ml PGN and incubated for 24 h. IL-10 concentrations were determined from the 
supernatants that were taken at the end of the incubation period using ELISA. Data are expressed as 
percent of vehicle (treated with vehicle for NECA+PGN). ***p<0.001 vs. vehicle+PGN, ###p<0.001 
vs. NECA+PGN/NT shRNA-transfected group. (D) BV-2 cells were treated with 0.1 μM 
isoproterenol or PGE2 and 20 μg/ml PGN for 24 h, and IL-10 concentrations were determined from 
the supernatants. Results (mean ± SEM) shown are representative of 3 separate experiments (n = 4 in 
each experiment). ###p< 0.001 vs. PGN. 
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expressing non-targeting shRNA (Figure 8C). In addition, other known cAMP-CREB-inducing 
agents, such as the β-adrenoceptor agonist isoproterenol or PGE2, also augmented IL-10 
production by PGN-treated BV-2 cells providing further evidence for the role of CREB in 
contributing to IL-10 production by microglia (Figure 8D). 
Next, we continued to characterize the signaling pathways contributing to the stimulatory 










Using Western detection of the phosphorylated, active forms of MAPKs p38, p42/44 and 
JNK, we found that PGN induced the activation of p38 (Figure 9A), p42/44 and JNK (Figure 
10A, C). In addition, NECA augmented the PGN-induced activation of p38 (Figure 9A), but it 
failed to increase the activation of p42/44 (Figure 10A) and JNK (Figure 10C). In addition, 
treatment with the p38 inhibitor SB203580 reversed, in a dose-dependent manner, the NECA 
augmentation of IL-10 production (Figure 9B). However, the p42/44 inhibitor PD98059 (Figure 
10B), and the JNK inhibitor Sp600125 failed to block the effect of NECA (Figure 10D). 
 
Figure 9. The stimulatory effect of NECA on IL-10 is p38-dependent. (A) BV-2 cells were 
treated with 10 μM NECA and 20 μg/ml PGN and 15 min later protein was isolated from the cells. 
Western blotting was performed using antibodies specific for p38 and phospho-p38. (B) BV-2 cells 
were pretreated with increasing concentrations of SB203580 30 min prior to treatment with 10 μM 
NECA and 20 μg/ml PGN for 24 h. IL-10 concentrations were determined from supernatants using 
ELISA. Data are shown as percentage of group treated with vehicle for inhibitor, NECA and PGN. 












Finally, we explored the role of the PI3K/Akt pathway. We found that NECA and PGN 
together induced the phosphorylation/activation of Akt (Figure 11A) and preventing PI3K/Akt 
activation with LY294002 reversed the stimulatory effect of NECA and PGN on IL-10 
production (Figure 11B). 
 
  
Figure 10. p42/44 and JNK do not contribute to the augmenting effect of NECA on PGN-induced 
IL-10 production. BV-2 cells were treated with 10 μM NECA and 20 μg/ml PGN for 15 min, and then 
protein was extracted from the cells. Western blotting was performed using antibodies specific for 
p42/44 and phospho–p42/44 (A) and phospho-JNK or actin (C). BV-2 cells were pretreated with 
increasing concentrations of PD98059 (B) or SP600125 (C) 30 min prior to treatment with 10 μM 
NECA and 20 μg/ml PGN for 24 h. IL-10 concentrations were determined from supernatants using 
ELISA. Data are shown as percentage of group treated with vehicle for inhibitor, NECA and PGN. 











In conclusion, A2BAR stimulation augments IL-10 production by TLR-activated 
microglia through a CREB-mediated transcriptional mechanism, which is dependent on the p38 
and PI3K/Akt pathways. 
 
5.4. Adenosine augments IL-4- and IL-13-induced alternative macrophage activation by a 
TLR4-independent mechanism 
 
We next studied whether adenosine signaling plays a regulatory role in alternatively 
activated macrophages. To begin to examine the effect of adenosine on alternative macrophage 
activation, RAW 264.7 macrophages were treated with adenosine immediately prior to treatment 
with IL-4. Figure 12 shows that adenosine augmented arginase activity (Figure 12A) as well as 
mRNA and protein levels of arginase-1 (Figure 12B and C) in IL-4-treated macrophages, but not 
in control cells.  
 
Figure 11. The effect of NECA/PGN is PI3K/Akt dependent. (A) BV-2 cells were treated with 10 
μM NECA and 20 μg/ml PGN and 15 min later protein was isolated from the cells. Western blotting 
was then performed using antibodies specific for Akt and phospho-Akt. (B) BV-2 cells were pre-
treated with LY294002 30 min prior to treatment with 10 μM NECA and 20 μg/ml PGN for 24 h. 
IL-10 concentrations were determined from supernatants using ELISA. Data are shown as 
percentage of group treated with vehicle for inhibitor, NECA and PGN. ***p<0.001 vs. vehicle. 












To explore the effect of adenosine on alternatively activated primary macrophages, TG-
elicited peritoneal macrophages from C57BL/6J mice were treated with adenosine and IL-4. 
Similar to RAW 264.7 macrophages, adenosine increased both IL-4-induced arginase activity 









Figure 12. Adenosine treatment augments arginase activity and expression in IL-4 treated 
macrophages. (A) RAW 264.7 macrophages were treated with 100 μM adenosine and at the same time 
stimulated with 5 ng/ml IL-4 for an additional 8 h, and then arginase activity was measured from the 
cell lysates. (B) RAW 264.7 macrophages were treated with 100 μM adenosine and 5 ng/ml IL-4, and 
arginase-1 mRNA levels were measured by real-time PCR using RNA isolated 3 h after stimulating 
with adenosine and IL-4. ***p<0.001 vs. control (con) group, ##p<0.01 vs. IL-4. Results (mean ± 
SEM) shown are representative of at least 3 experiments with n=6 in each experiment. (C) RAW 264.7 
cells were challenged with IL-4 in the presence or absence of adenosine or NECA for 8 h and arginase-
1 protein level was determined from cell extracts using Western blotting with antibodies raised against 
arginase-1. -actin was utilized as internal control. The figure is representative of 3 separate 
experiments. 
Figure 13. Adenosine augments arginase activity and arginase-1 expression in primary 
macrophages. (A) Mouse peritoneal macrophages were treated with 100 μM adenosine and 5 ng/ml 
IL-4 for 24 h, and then arginase activity was measured from the cell lysates. Results (mean ± SEM) 
shown are representative of at least 3 experiments with n=6 in each experiment. ***p<0.001 vs. con, 
##p<0.01 vs. IL-4. (B) Peritoneal macrophages were obtained from male C57BL/6J mice, and were 
treated with 100 μM adenosine and 5 ng/ml IL-4. After 4, 8, 12, or 24 h of incubation, arginase-1 
mRNA abundance was measured using real-time PCR. Results (mean ± SEM) shown are representative 
of at least 3 experiments with n=6 in each experiment. *p<0.05 vs. IL-4. 
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We next studied the effect of AR activation on TIMP-1 production. We found that IL-4 
induced both TIMP-1 release into the medium and TIMP-1 mRNA accumulation in peritoneal 
macrophages. In addition, adenosine increased both IL-4-induced TIMP-1 release and mRNA 











The effect of IL-4 or adenosine/IL-4 did not require TLR4, because IL-4 induced, and 
adenosine enhanced IL-4-induced TIMP-1 release by both wild-type (WT) and TLR4 knockout 
(KO) macrophages (Figure 14C). Additionally, adenosine or NECA augmented mgl-1 mRNA 
accumulation in IL-4-challenged macrophages (Figure 15A and B). 
  
Figure 14. Adenosine augments TIMP-1 production by alternatively activated macrophages. (A) 
Peritoneal macrophages were treated with 100 μM adenosine and 5 ng/ml IL-4 for the indicated times 
and then TIMP-1 was measured from the supernatants using ELISA. Results (mean ± SEM) shown are 
representative of at least 3 experiments with n=4 in each experiment. **p<0.01 and ***p<0.001 vs. IL-
4. (B) Peritoneal macrophages were stimulated with 100 μM adenosine and 5 ng/ml IL-4, and TIMP-1 
mRNA levels were measured by real-time PCR using RNA isolated 8 h after adenosine/IL-4. Results 
(mean ± SEM) shown are representative of at least 3 experiments with n=6 in each experiment. 
**p<0.01 vs. con, ##p<0.01 vs. IL-4. (C) Peritoneal macrophages were obtained from TLR4 KO and 
WT mice and treated with IL-4 or adenosine and IL-4 for 24 h, after which period TIMP-1 production 
was determined from the supernatants. Results (mean ± SEM) shown are representative of at least 2 










To confirm the stimulatory effect of adenosine on alternative macrophage activation, we 
studied the effect of adenosine on IL-13-induced arginase-1 mRNA accumulation and arginase 
activity in RAW264.7 macrophages, as well as on IL-13-stimulated TIMP-1 expression in 
peritoneal macrophages. We found that adenosine upregulated IL-13-induced arginase activity 









Figure 15. AR activation augments IL-4-stimulated mgl-1 mRNA accumulation in RAW 264.7 
cells. RAW 264.7 macrophages were treated with 100 μM adenosine (A) or 3 μM NECA (B) and 5 
ng/ml IL-4, and mgl-1 mRNA levels were measured by real-time PCR using RNA isolated 3 h after 
stimulating with adenosine or NECA and IL-4. Results (mean ± SEM) shown are representative of at 
least 3 experiments with n=4 in each experiment. ***p<0.001 or **p<0.01 vs. con, #p<0.05 or 
##p<0.01 vs. IL-4. 
Figure 16. Adenosine augments arginase activity and expression and TIMP-1 release in IL-13 
stimulated macrophages. (A) RAW 264.7 macrophages were treated with 100 μM adenosine and 
challenged with 5 ng/ml IL-13 for 8 h, and then arginase activity was measured from the cell lysate. 
***p<0.001 vs. control (con), ##p<0.01 vs. IL-13. Results (mean ± SEM) shown are representative of 3 
experiments with n=6 in each experiment. (B) RAW 264.7 macrophages were treated with 100 μM 
adenosine and challenged with 5 ng/ml IL-13 for 8 h, and mRNA abundance was measured using real-
time PCR. Results (mean ± SEM) shown are representative of at least 3 experiments with n=6 in each 
experiment. **p<0.01 vs. control , and #p<0.05 vs. IL-13. (C) Peritoneal macrophages were treated 
with 100 μM adenosine and challenged with 5 ng/ml IL-13 for 24 h and then TIMP-1 levels were 
measured from the supernatants using ELISA. Results (mean ± SEM) shown are representative of at 
least 3 experiments with n=6 in each experiment. **p<0.01 vs. control, and ##p<0.01 vs. IL-13. 
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Because adenosine was more efficacious in increasing arginase activity and failed to 
upregulate TIMP-1 release (data not shown) in RAW 264.7 macrophages, in the following 
experiments we used RAW 264.7 and peritoneal macrophages, to study the mechanism of the 
adenosine-induced upregulation of arginase-1 and TIMP-1, respectively.  
 
5.5. Role of A2A and A2B ARs in mediating the stimulatory effect of adenosine on 
alternative macrophage activation 
 
To investigate which ARs are responsible for mediating the stimulatory effect of 
adenosine on IL-4-induced arginase activity and TIMP-1 production, we pretreated macrophages 
with specific AR agonists before IL-4 stimulation. We found that NECA increased both arginase 
activity (EC50=261.8nM) and TIMP-1 production (EC50=80.67nM) by IL-4-stimulated 
macrophages (Figure 17A and B). Furthermore, NECA increased IL-4-induced arginase-1 
protein expression (Figure 12C). The EC50 values of NECA were indicative of a role for A2BARs 
(Feoktistov and Biaggioni, 1993; Feoktistov and Biaggioni, 1998). In contrast, relevant 
concentrations of CCPA or 2-Cl-IB-MECA failed to mimic the stimulatory effect of adenosine, 
and CGS21680 was marginally effective at increasing TIMP-1 release but not arginase activity 







Figure 17. Effect of AR agonists on arginase activity and TIMP-1 production. (A)  RAW 264.7 
macrophages were treated with AR agonists and stimulated with IL-4 for 8 h, and then arginase activity 
was measured from the cell lysate. Results (mean ± SEM) shown are representative of at least 3 
experiments with n=6 in each experiment. ***p<0.001 vs. vehicle. (B) Peritoneal macrophages were 
treated with AR agonists and stimulated with IL-4 for 24 h, and TIMP-1 concentrations were 
determined in the supernatants. Results (mean ± SEM) shown are representative of at least 3 
experiments with n=6 in each experiment. *p<0.05 vs. vehicle; ***p<0.001 vs. vehicle. 
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To further investigate the role of A2BARs, we also employed A2BAR KO mice. The 
results confirmed that the A2BAR is important for the stimulatory effect of adenosine on IL-4-
induced TIMP-1 production, because both adenosine and NECA were incapable of upregulating 
TIMP-1 production by macrophages isolated from A2BAR KO mice (Figures 18A and B). Similar 
to genetic blockade of A2BARs, pharmacological antagonism by 100 nM PSB0778 inhibited both 
the NECA enhancement of arginase activity and TIMP-1 production (Figure 19A and B). The 
effect of PSB0778 was independent of A2AARs, because PSB0778 prevented the NECA 








PSB0778 prevented the NECA enhancement of TIMP-1 release in WT cells (Figure 
19B), which could be construed as pointing to an exclusive role for the A2BAR in mediating the 
effect of adenosine. However, because PSB0778 has not been pharmacologically characterized in 
murine systems in detail and because A2AARs have been widely implicated in regulating 
macrophage function (Hasko et al., 2007), we further studied the role of A2AARs by employing 
A2AAR KO mice. Our results indicated that the A2AAR contributed, although to a lesser degree, 
to the upregulation of TIMP-1 production, as both adenosine and NECA were less efficacious in 
upregulating TIMP-1 production by macrophages obtained from A2AAR KO mice than from their 
WT littermates (Figure 18A and B). 
Figure 18. Effect of AR stimulation on alternative macrophage activation of WT, A2AAR KO or 
A2BAR KO macrophages. Peritoneal macrophages isolated from A2AAR KO, A2BAR KO and WT 
mice were treated with adenosine and stimulated with 5 ng/ml IL-4 (A) or NECA (B) for 24 h, and then 
TIMP-1 levels were measured from the supernatants using ELISA. Results (mean ± SEM) shown are 












5.6. C/EBP  is required but CREB and STAT-6 are dispensable for the stimulatory effect 
of adenosine on arginase-1 expression in IL-4-stimulated macrophages 
 
Since the mechanisms of the IL-4 activation of arginase-1 transcription have been 
investigated in detail (Gray et al., 2005; Pauleau et al., 2004; Ruffell et al., 2009), and because 
nothing is known about how IL-4 affects TIMP-1 transcription, we studied the mechanism of 
action of adenosine in enhancing arginase-1 transcription. Using a previously described arginase-
1 promoter luciferase construct (Pauleau et al., 2004), we showed that either adenosine or NECA 
enhanced IL-4-induced arginase-1 promoter activity (Figure 20A). We then focused our effort on 
3 transcription factors that have been implicated in regulating alternative macrophage activation, 
C/EBP , CREB and STAT-6 (Gray et al., 2005; Pauleau et al., 2004; Ruffell et al., 2009). Since 
we recently demonstrated that adenosine upregulates bacteria-induced C/EBP  activation (Csoka 
et al., 2007), we first examined the role of C/EBP . We found that either adenosine or IL-4 alone 
was unable to increase C/EBP transcriptional activity; however, adenosine and IL-4 together 
synergistically induced C/EBP transcriptional activity (Figure 20B). To provide further insight 
into the role of C/EBP  in regulating arginase-1 expression, C/EBP  WT and KO immortalized 
Figure 19. PSB0778 blocks the stimulatory effect of NECA on alternative activation of 
macrophages. (A) RAW 264.7 macrophages were pretreated with 10-1000 nM PSB0778 30 min prior 
to treatment with NECA and IL-4 for 8 h, and then cell lysates were prepared for arginase 
measurements. Results (mean ± SEM) shown are representative of at least 3 experiments with n=6 in 
each experiment. **p<0.01 vs. IL-4; #p<0.05 vs. IL-4/NECA and ##p<0.01 vs. IL-4/NECA. (B) WT 
and A2AAR KO peritoneal macrophages were pretreated with 100 nM PSB0778 30 min prior to 
treatment with NECA and IL-4 for 24 h. TIMP-1 levels were measured from the supernatants using 
ELISA. Results (mean ± SEM) shown are representative of at least 3 experiments with n=6 in each 
experiment. ***p<0.001 vs. vehicle; ###p<0.001 vs. IL-4; $$$p<0.001 vs. IL-4/NECA. 
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macrophage cell lines (Albina et al., 2005; Gorgoni et al., 2002) were stimulated with adenosine 
and IL-4, and then arginase activity was measured. As Figure 20C shows, IL-4 increased 
arginase activity in both WT and KO macrophages, and adenosine upregulated this activity by 













It is noteworthy that similar to the results of a previous study (Albina et al., 2005), IL-4 
induced a more pronounced increase in arginase activity in C/EBP  KO than WT cells, which 
may be a consequence of compensatory upregulation of other C/EBP factors. These data together 
identify C/EBP  as a major transcription factor mediating the stimulatory effect of adenosine on 
arginase-1 expression in IL-4-activated macrophages. 
A recent study documented that CREB-mediated C/EBP  induction is required for the 
upregulation of alternative activation-specific genes, including arginase-1 (Ruffell et al., 2009). 
Furthermore, adenosine activates CREB in macrophages (Nemeth et al., 2003). Therefore, 
Figure 20. The stimulatory effect of adenosine on arginase-1 transcription is mediated by 
C/EBPβ. (A) RAW 264.7 cells were transiently transfected with promoter-luciferase reporter 
constructs containing -3810/-31 fragment of the arginase-1 promoter in a pGL3 basic vector. Cells were 
treated with adenosine or NECA and IL-4 for 8 h. Luciferase reporter activities were normalized to 
control treatment. Results (mean ± SEM) shown are representative of at least 3 experiments with n=5 in 
each experiment. **p<0.01 vs. control, #p<0.05 and ##p<0.01 vs. IL-4. (B) RAW 264.7 macrophages 
were transfected with a luciferase reporter vector driven by C/EBP (pC/EBP-luc). Cells were treated 
with adenosine (ado; 100 M) and IL-4 for 4 h, and luciferase activity was determined from cell 
lysates. Luciferase reporter activities were normalized to protein concentration. Results (mean ± SEM) 
shown are representative of at least 3 experiments with n=4 in each experiment. **p<0.01 vs. IL-4 or 
ado. (C) C/EBP  WT and KO macrophages were activated with IL-4 or adenosine plus IL-4, and 
arginase activity was determined from the cell lysate following an 8-h stimulation. Results (mean ± 
SEM) shown are representative of at least 3 experiments with n=6 in each experiment. ***p<0.001 vs. 
control (con), and ###p<0.001 vs. IL-4 in C/EBP  KO cells. 
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utilizing lentivirally-delivered shRNA to downregulate CREB expression, we assessed whether 
CREB is required for the stimulatory effect of adenosine on IL-4-induced arginase expression. 
We first confirmed using Western blotting that RAW 264.7 cells that were stably transduced with 
lentivirally-delivered CREB shRNA expressed negligible levels of CREB protein when 
compared to cells transduced with a control vector expressing non-targeting (NT) sequences 










We, then, stimulated macrophages with IL-4 or adenosine plus IL-4 and measured 
arginase activity. As Figure 21B shows, arginase activity was induced by IL-4 and was further 
upregulated by adenosine in both NT shRNA- and CREB shRNA-expressing macrophages. 
These results indicate that CREB is not necessary for the stimulatory effect of adenosine on 
arginase expression. 
Additionally, we excluded a role for STAT-6 in mediating the augmenting effect of 
adenosine on arginase activity, as we found that IL-4-induced STAT-6 activation was not 
increased but actually decreased by adenosine (Figure 22). 
 
Figure 21. The stimulatory effect of adenosine on arginase activity is independent of CREB.  
RAW 264.7 cells were transduced with lentivirus particles containing either CREB-specific shRNA or 
non-targeting (NT) shRNA. CREB-silenced or NT-transduced cells were selected in the presence of 
puromycin. (A) CREB protein levels were evaluated by Western blotting using protein extract isolated 
from NT shRNA- and CREB shRNA-transduced RAW 264.7 macrophages. Results shown are 
representative of at least 3 experiments. (B) CREB-silenced or NT-transduced macrophages were 
stimulated with adenosine and IL-4, and arginase activities were measured from the cell extracts. 
Results (mean ± SEM) shown are representative of at least 3 experiments with n=6 in each experiment. 









5.7. Role of intracellular kinases in mediating the effect of adenosine on alternative 
macrophage activation 
 
Previous studies have shown that both IL-4 and adenosine can activate various 
intracellular kinases, including JAK 1 and 3, Shc, PI3K, Akt, as well as p38, p42/44, and JNK 
MAPKs. To dissect the role of these kinases in mediating the stimulatory effect of adenosine on 
alternative macrophages activation, we first sought to detect using Western blot analysis the 
active, phosphorylated forms of these kinases. We found that both adenosine and IL-4, both 
alone and in combination, failed to induce JAK 1/3, Shc, PI3K, Akt, p42/44, and JNK activation 
(data not shown), but adenosine alone and in combination with IL-4, but not IL-4 alone, 
upregulated p38 activation (Figure 23A). We then pretreated macrophages with SB203580, a 
selective p38 pathway inhibitor, 30 minutes prior to adenosine and IL-4 exposure to examine the 
role of p38. SB203580 prevented the increasing effect of adenosine on both arginase activity 
(Figure 23B) and TIMP-1 release (Figure 23C), confirming that p38 mediates the stimulatory 
effect of adenosine on alternative macrophage activation. 
 
Figure 22. Adenosine inhibits IL-4-induced STAT-6 activation. Peritoneal macrophages were 
challenged with 5 ng/ml IL-4 in the presence or absence of adenosine (100 M) for the indicated times 
and STAT-6 phosphorylation, which is indicative of activation, was determined from cell extracts taken 
at the end of the incubation periods using Western blotting with antibodies raised against active, 
phosphorylated STAT-6. -actin was employed as an internal control. The figure is representative of 3 






   
Figure 23. p38 activation is required for the stimulatory effect of adenosine on alternatively 
activated macrophages. (A) Macrophages were treated with IL-4 in the presence or absence of 
adenosine for 20 minutes. p38 activation was determined from cell extracts using immunoblotting with 
antibodies raised against the active, doubly-phosphorylated form of p38. -actin was used as internal 
control. This figure is representative of 3 separate experiments. (B) RAW 264.7 macrophages were 
pretreated for 30 min with SB203580 before adding 100 M adenosine and 5 ng/ml IL-4. After 8 h of 
incubation, arginase activities were assessed. Results (mean ± SEM) shown are representative of at 
least 3 experiments with n=6 in each experiment. ***p<0.001 vs. IL-4, ##p<0.01 vs. adenosine/IL-4. 
(C) Peritoneal macrophages were pretreated for 30 min with SB203580 before adding adenosine and 
IL-4. 24 h later, supernatants were collected. TIMP-1 levels were assessed from the supernatants using 
ELISA. Results (mean ± SEM) shown are representative of at least 3 experiments with n=6 in each 





6.1. Stimulatory effect of AR activation on IL-10 production by microglia  
 
Here we have provided evidence that adenosine in conjunction with TLR ligands 
augments the release of IL-10 by murine microglial cells. Using AR agonists and antagonist, we 
have demonstrated that the A2BAR is primarily responsible for the stimulatory effect of 
adenosine on IL-10 production. Specifically, we found that the order of potency of agonists was 
NECA>IB-MECA>CCPA≥CGS21680, which indicates a predominant role for A2BARs in 
triggering IL-10 production (Feoktistov and Biaggioni, 1997). In addition, the fact that the 
A2BAR antagonist MRS1754 but not antagonists of the other ARs reversed the stimulatory effect 
of both adenosine and NECA on IL-10 production, lends further credence to the proposal that 
A2BARs are the most important ARs in augmenting IL-10 production by activated microglia. In 
agreement with a primary role for A2BARs, mRNA levels of A2BARs were highest after PGN- 
and LPS-treatment of BV-2 cells. Interestingly, while we found that the expression level of 
A2BAR and A3AR mRNAs was comparable in unstimulated BV-2 cells, a previous study by 
Haselkorn et al. showed that the expression of A2BAR mRNA was highest of all the ARs in 
unstimulated BV-2 cells (Haselkorn et al., 2010). Nevertheless our results in primary microglia 
showed a similar pattern of AR expression because the amount of A2BAR mRNA was largest in 
either unstimulated or TLR-stimulated cells. 
We have also confirmed the previously described inhibitory effect of adenosine on the 
LPS-induced production of TNF-α and IL-12 by microglia (Lee et al., 2006; van der Putten et al., 
2009). In addition, we showed for the first time, that adenosine also diminishes IL-6 production 
by microglial cells activated with different TLR agonists.  Although we did not investigate the 
role of the various ARs in suppressing the production of proinflammatory cytokines in the 
current study, it appears that different ARs regulate the production of pro- vs. anti-inflammatory 
cytokines by microglia. That is because while the inhibitory effect of adenosine on IL-12 and 
TNF-α has been found to be A2AAR- or A3AR-dependent (Lee et al., 2006; van der Putten et al., 
2009), our data show that A2B receptors mediate the stimulatory effect of adenosine on IL-10 
production. 
Our data revealed that A2BAR stimulation increased IL-10 mRNA levels in BV-2 cells via 
a transcriptional mechanism, as this effect could be completely prevented when transcription was 
blocked using actinomycin D. This result was unexpected in microglia, because we previously 
showed that A2BAR stimulation augmented IL-10 production by a translational mechanism in 
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TLR-activated macrophages (Nemeth et al., 2005). These observations indicate that A2BAR 
activation differentially regulates IL-10 production by microglia vs. macrophages. Using a 
number of approaches, we have pinpointed CREB as the transcription factor that mediates the 
stimulatory effect of AR stimulation on IL-10 transcription. First, employing mutant IL-10 
promoter constructs, we showed that a CREB-harboring region of the IL-10 promoter was 
necessary for the stimulatory effect of AR stimulation. Secondly, we showed that CREB 
phosphorylation occurs at the IL-10 promoter in response to AR stimulation in BV-2 cells. 
Thirdly, we demonstrated that silencing CREB prevents the effect of AR stimulation on IL-10 
release. Previous studies have linked the induction of IL-10 transcription to CREB in different 
cell types, such as macrophages treated with adiponectin (Park et al., 2008) or LPS (Avni et al., 
2010), and in dendritic cells stimulated with the fungal cell wall product zymosan or IFN-β 
(Alvarez et al., 2009; Wang et al., 2011). However, our study is the first one to show that IL-10 
induction relies on CREB in microglia. 
We have previously noted that AR stimulation enhances CREB phosphorylation and 
transcriptional activity through a p38-dependent manner in macrophages (Nemeth et al., 2003). 
The results of the present study with microglia also suggest a role of p38 in stimulating both 
CREB activation and IL-10 release, as AR signaling augmented p38 phosphorylation, and 
pharmacological inhibition of p38 blocked both the CREB and the IL-10 responses to AR 
activation. Although p42/44 had also been linked to CREB activation and IL-10 transcription 
(Park et al., 2008), we found that AR stimulation failed to induce the phosphorylation of p42/44 
and pharmacological inhibition of p42/44 failed to prevent the stimulatory effect of AR 
activation on IL-10 production of microglia. Thus, p42/44 is not required for the stimulatory 
effect of AR activation on IL-10 production by microglia. 
The participation of the PI3K/Akt pathway in AR signaling has been proposed by several 
previous studies (Kuno et al., 2008; Schulte and Fredholm, 2003a; Solenkova et al., 2006; Wang 
et al., 2011). Our results show that AR activation augments IL-10 production by activating the 
PI3K/Akt pathway, but this pathway is independent of CREB. Our findings, thus, extend 
previous observations, which showed that PI3K/Akt activation augments IL-10 production in 
macrophages and dendritic cells (Lee et al., 2009; Polumuri et al., 2007; Saegusa et al., 2007). 
Adenosine has been described to play regulatory roles in several CNS conditions, and the 
role of the various AR subtypes varies. It has been shown that A1AR KO mice develop worsened 
demyelination and axonal injury after EAE compared to WT littermates (Tsutsui et al., 2004), 
indicating A1AR -mediated protection. The concentrations of IL-10 were lower in the spinal cord 
of A1AR deficient mice with EAE compared to WT animals, but there was no difference in the 
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levels of TNF-α (Tsutsui et al., 2004). These results suggest that in addition to A2BARs, the 
A1ARs may also contribute to the regulation of IL-10 expression in the brain. It is noteworthy 
that the source of IL-10 was not identified in this study. Also implicating A1ARs in CNS 
protection is the observation that stimulating the A1AR has been shown to be neuroprotective 
after traumatic brain injury, as well, an effect which was associated with a decreased microglial 
inflammatory response (Haselkorn et al., 2010). In contrast, Dai and coworkers showed that 
A2AAR stimulation mediates the protective effects of adenosine in traumatic brain injury by 
decreasing TNF-α and IL-1β expression, albeit interestingly only in case of low glutamate 
concentrations. Stimulation of A2AAR by CGS21680 at a time when glutamate concentration was 
high augmented TNF-α expression in the brain and aggravated brain damage caused by traumatic 
injury (Dai et al., 2010). Duan and coworkers provided further evidence for the neuroprotective 
role of A2AAR showing that cerebral IL-6 and TNF-α levels were higher and brain damage was 
more severe in A2AAR KO mice with chronic cerebral hypoperfusion relative to WT mice (Duan 
et al., 2009). It is noteworthy that A2ARs sometimes have proinflammatory effects in CNS 
ischemic/inflammatory diseases (Chen et al., 1999; Li et al., 2009a; Rebola et al., 2011), and the 
protective vs. injurious effects are dependent on various factors, such as the type of insult and the 
ambient glutamate concentrations. Finally, stimulation of the A3AR decreased ischemic injury in 
the brain and inhibited the migration of microglia to the inflammation site, as well as the release 
of TNF-α and IL-1β (Choi et al., 2011). Thus, A1ARs, A2AARs and A3ARs have been described 
to play important protective roles in different brain disorders, and some of these protective 
effects are mediated by ARs expressed on microglia. Since the inflammatory response of 
microglia is an important contributor to the pathophysiology of virtually all ischemic, 
inflammatory, and neurodegenerative diseases (Polazzi and Monti, 2010), our data showing that 
A2BAR activation augments IL-10 production by microglia point to an anti-inflammatory and 
protective role of A2BAR activation in the brain. We propose that targeting A2BARs may be a 





6.2. Adenosine enhances the alternative activation of macrophages 
 
Macrophages can respond to endogenously released mediators that are generated during 
infectious or injurious stimuli. Adenosine has been shown to be a broad inhibitor of the 
proinflammatory consequences of classical macrophage activation. For example, adenosine 
suppresses the LPS-induced production of proinflammatory cytokines, such as TNF-α and IL-12 
(Hasko et al., 2000), the chemokine macrophage inflammatory protein-1 (Szabo et al., 1998), and 
the release of proinflammatory mediators such as NO (Hasko et al., 1996). The stimulatory effect 
of adenosine on IL-10 production also contributes to the control of the proinflammatory 
responses of classically activated macrophages.  
Our results with IL-4- and IL-13-stimulated macrophages show, for the first time, that 
adenosine enhances alternative macrophage activation. The effects of adenosine in promoting 
alternative macrophage activation are less broad than the wide-ranging inhibitory effects of 
adenosine on classical macrophage activation, as adenosine increased the expression of key 
alternative markers arginase-1, TIMP-1, and mgl-1, but not that of Ym1 and Fizz1 (data not 
shown). 
The current consensus is that the regulatory effects of adenosine on classically activated 
macrophages are mediated primarily by A2AAR and secondarily by A2BAR. One of the best 
characterized effects of adenosine on macrophages is its capacity to suppress the production of 
TNF-α. The dominant role of the A2AAR in the inhibition of TNF-α production has been 
confirmed in macrophages and monocytes of both human (Buenestado et al., 2010; Zhang et al., 
2005) and mouse origin (Kreckler et al., 2006; Ryzhov et al., 2008b). However, recent data show 
that A2BAR stimulation can also decrease TNF-α production by mouse macrophages (Chen et al., 
2009; Kreckler et al., 2006). The augmenting effect of adenosine on IL-10 is also mediated by 
both A2AAR and A2BAR. E.coli-induced IL-10 production in peritoneal macrophages has been 
found to be enhanced by A2AAR stimulation (Csoka et al., 2007). However, the stimulatory effect 
of adenosine on the IL-10 expression in LPS-induced RAW 264.7 macrophages was mediated by 
the A2BAR (Nemeth et al., 2005). 
 The stimulatory effects of adenosine on alternative macrophage activation are mediated 
predominantly by A2BAR, which contrasts with the preeminent role of A2AAR in regulating 
classical macrophage activation (Hasko et al., 2007). This preeminent role of A2BAR was 
confirmed by the observations that the stimulatory effects of adenosine and NECA on arginase 
expression and TIMP-1 release were completely prevented by both A2BAR KO and 
pharmacological A2BAR antagonism. In addition, NECA was by far the most potent agonist of all 
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the AR agonists tested, which further incriminates the A2BAR (Feoktistov and Biaggioni, 1997). 
A lesser involvement of A2AAR is underlined by our results showing that both adenosine and 
NECA were less efficacious in increasing TIMP-1 production by macrophages isolated from 
A2AAR KO mice as compared to their WT counterparts. It is noteworthy that although 
CGS21680 had a marginal, albeit significant, increasing effect on TIMP-1 production, it failed to 
augment arginase activity. Thus, A2AAR and A2BAR differentially regulate distinct features of 
alternative macrophage activation. 
We found that AR stimulation upregulated IL-4-induced mRNA and protein 
accumulation of both arginase-1 and TIMP-1. In addition, similar to its stimulatory effect on 
arginase-1 mRNA accumulation (Figures 12B and 13B), AR stimulation enhanced IL-4-induced 
arginase-1 promoter activity. Previous studies have proposed that arginase-1 promoter activity in 
macrophages is regulated by STAT-6 and C/EBP  (El Kasmi et al., 2008; Gray et al., 2005; 
Pauleau et al., 2004; Qualls et al., 2010). Since AR stimulation decreased IL-4-induced STAT-6 
activation (Figure 22), we concluded that STAT-6 activation does not mediate the upregulation 
of arginase-1 following AR stimulation. In contrast, because IL-4-induced C/EBP -deficient 
macrophages failed to upregulate arginase activity following AR stimulation, we conclude that 
C/EBP  mediates the stimulatory effect of AR stimulation on arginase-1 expression. This notion 
is supported by our data that AR stimulation synergizes with IL-4 to upregulate C/EBP 
transcriptional activity. This conclusion, together with previous observations of our research 
group that C/EBP  is required for the enhancing effect of adenosine on Eschericia coli-induced 
IL-10 production (Csoka et al., 2007) is consistent with the idea that C/EBP  represents an 
important focal point, which orchestrates the effects of adenosine in macrophages (Hasko et al., 
2008). 
It was reported recently that binding of CREB to C/EBP  promoter elements is critical 
for the activation of C/EBP -induced arginase-1 transcription in infiltrating macrophages 
following muscle injury (Ruffell et al., 2009). The ability of ARs to stimulate CREB in 
macrophages had been described previously (Nemeth et al., 2003) and was confirmed in our 
studies on microglia discussed above. Based on these observations and previous data showing 
that cAMP can upregulate arginase-1 expression (Erdely et al., 2006), we hypothesized that 
adenosine should upregulate IL-4-induced arginase activity via CREB activation. However, we 
excluded a role for CREB in this upregulation, as shRNA-mediated CREB silencing in 
macrophages failed to reverse the adenosine increase of arginase activity in IL-4-induced 
macrophages. Nevertheless, it is possible that cAMP contributed to the effect of adenosine in 
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enhancing alternative macrophage activation in a CREB-independent fashion. Further studies are 
needed to determine the role of cAMP in mediating the stimulatory effect of AR activation on 
alternative macrophage activation. 
MAPKs are important for transmitting extracellular stressful signals toward the nucleus. 
IL-4 has been shown to induce p42/44 and JNK activation in certain cell types, including 
monocytes (Deszo et al., 2004), airway epithelial cells (Kim et al., 2009) and neutrophils (Ratthe 
et al., 2007). Additionally, adenosine stimulates p42/44 and JNK activation in various immune 
and non-immune cell types (Hasko et al., 2008; Jacobson and Gao, 2006). However, we found 
that either IL-4 or adenosine failed to activate p42/44 and JNK in macrophages. IL-4 also 
activates p38 MAPK signaling in a cell type-dependent manner; IL-4 increased p38 activation in 
a murine macrophage cell line, but failed to influence p38 activation in B and T cell lines (Hunt 
et al., 2002). In addition, both A2AAR and A2BAR can activate MAPK signaling and adenosine 
has been reported to be capable of activating p38 in macrophages (Csoka et al., 2007; Feoktistov 
et al., 1999; Nemeth et al., 2003). We found that although IL-4 had no effect on p38 activation, 
adenosine alone or in combination with IL-4 increased p38 activation (Figure 23A). In addition, 
inhibiting the p38 pathway prevented the stimulatory effect of adenosine on IL-4-induced 
arginase activity and TIMP-1 release (Figures 23B and C). Since p38 was also essential for the 
stimulatory effect of adenosine on IL-10 production by bacteria- and LPS-stimulated 
macrophages (Csoka et al., 2007; Nemeth et al., 2005) and in PGN-stimulated microglia, we 
propose that p38 is another central factor in mediating the regulatory effects of adenosine on both 
classical and alternative macrophage activation. 
As noted in the results section, due to the fact that adenosine failed to upregulate TIMP-1 
secretion by RAW 264.7 macrophages, we did not study in a detailed manner the intracellular 
mechanisms of how AR activation augments TIMP-1 release. It is plausible that distinct 
intracellular pathways mediate the augmenting effect of adenosine on TIMP-1 production vs. 
arginase-1 expression. Further studies are warranted to delineate the intracellular signaling 
pathways leading to the stimulatory effect of adenosine on TIMP-1 release by alternatively 
activated macrophages. 
Alternatively activated macrophages are important for defense against extracellular 
parasites (Noel et al., 2004). In this regard, our data that A2B receptors augment alternative 
macrophage activation are in agreement with our unpublished observations that A2B receptors are 
crucial for protection against mouse intestinal nematode parasite, Heligmosomoides polygyrus 
(W.C. Gause, B. Koscsó, G. Haskó, B. Csóka, and N. Patel, unpublished data). This A2BAR-
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mediated protection correlated with the degree of alternative macrophage activation in the 
infected mice (W.C. Gause, B. Koscsó, G. Haskó, B. Csóka, and N. Patel, unpublished data). 
In certain disease situations, however, alternatively activated macrophages can contribute 
to the progression of disease. For example, it has been proposed that macrophages activated by 
IL-4 and IL-13 during asthma and chronic obstructive pulmonary disease (COPD) contribute to 
airway remodeling and lung fibrosis leading to lung dysfunction (Gordon, 2003; Noel et al., 
2004; Van Ginderachter et al., 2006). There is substantial evidence that adenosine can induce 
bronchoconstriction in patients with asthma or COPD but not in healthy individuals, and that 
adenosine levels are elevated in the bronchoalveolar lavage fluid and exhaled breath condensate 
of patients with asthma (Cushley et al., 1983; Driver et al., 1993; Huszar et al., 2002). Adenosine 
augments proinflammatory cytokine and chemokine release from bronchial smooth muscle 
(Zhong et al., 2004) and epithelial cells (Zhong et al., 2006) and induces IL-4, IL-13 and IL-8 
secretion by mast cells (Feoktistov and Biaggioni, 1995; Ryzhov et al., 2004), all of which are 
mediated through A2BARs. Pharmacological blockade of A2BARs ameliorates the pulmonary 
inflammation and fibrosis in adenosine deaminase KO mice, providing further evidence for the 
deleterious role of A2BAR stimulation in chronic airway inflammation (Sun et al., 2006). In 
addition, allergen-induced chronic pulmonary inflammation is attenuated in A2BAR KO mice 
compared to WT littermates (Zaynagetdinov et al., 2010). Theophylline is a non-selective AR 
antagonist that is widely used in asthma therapy, because of its inhibitory effect on 
bronchoconstriction. It is believed that theophylline exerts its effects by blocking A2BARs on 
mast cells (Caruso et al., 2009; Feoktistov et al., 1998; Polosa and Blackburn, 2009). Based on 
our results we propose that the inhibition of alternative activation of macrophages may be 
another mechanism by which theophylline ameliorates the symptoms of asthma. 
It is now becoming increasingly clear that alternatively activated macrophages are 
hijacked by tumor cells to function as suppressors of anti-tumor T cell responses and stimulators 
of tumor angiogenesis (Mantovani et al., 2004; Van Ginderachter et al., 2006). Recently 
published results show that A2BAR contribute to tumor progression. A2BAR stimulation on DCs 
leads to aberrant differentiation and generation of a proangiogenic and tolerogenic phenotype. 
Injection of DCs with this phenotype to tumors results in growth promotion (Novitskiy et al., 
2008). A2BAR KO mice exhibit attenuated tumor growth and longer survival after inoculation 
with lung carcinoma cells compared to WT littermates (Ryzhov et al., 2008a). In addition, 
pharmacological blockade of A2BAR inhibits breast tumor growth by enhancing DC activation 
and antitumor responses (Cekic et al., 2012). Tumor progression is strongly regulated by 
myeloid-derived suppressor cells and tumor-associated macrophages (Laoui et al., 2011; 
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Ostrand-Rosenberg and Sinha, 2009). The phenotype of both populations shows similarities to 
alternatively activated macrophages; for example, both show increased arginase-1 expression 
(Rodriguez and Ochoa, 2008). Thus, the stimulatory effect of A2BAR stimulation on the 
alternative activation of macrophages may contribute to tumor progression, further highlighting 
the therapeutic potential of inhibiting this AR subtype in the treatment of cancer. 
Finally, it is well established that alternatively activated macrophages also participate in 
wound healing (Murray and Wynn, 2011b). In addition, adenosine has been implicated as a 
contributor to wound healing, in part because it augments the release of the crucial angiogenic 
factor VEGF by macrophages (Ernens et al., 2010; Leibovich et al., 2002). The effect of 
adenosine on VEGF involves both A2AARs and A2BARs (Gessi et al., 2010). Similar to VEGF, 
we found that in alternatively activated macrophages, A2BARs mediate the augmenting effect of 
adenosine on TIMP-1 expression and A2AARs also contribute the process. As TIMP-1 is an 
important regulator of tissue remodeling, our data provide further insights into the actions of 
adenosine in wound healing and suggest that stimulating either A2AARs or A2BARs may be used 
for the therapeutic management of patients with impaired wound healing. 
In conclusion, we have shown that the A2BAR regulates the function of both classically 
activated microglia and alternatively activated macrophages. A2BAR stimulation upregulates IL-
10 production by microglia activated with TLR ligands. A2BARs augment arginase-1 expression 
and activity in alternatively activated macrophages. A2BARs, and to a lesser extent A2AARs, also 
increase IL-4-induced TIMP-1 production. As the A2BAR exerts a regulatory role in wide range 
of macrophage populations with different activation profiles, targeting this receptor has a 
widespread therapeutic potential in neuroinflammatory and neurodegenerative diseases and 
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A patogénhez asszociált molekuláris mintázatok által aktivált mikrogliák gyulladáskeltő 
citokineket termelnek, például tumor nekrózis faktor (TNF)-α, interleukin (IL)-6 és IL-12, valamint 
gyulladáscsökkentő citokineket szekretálnak, amelyek közül a legfontosabb az IL-10. Az adenozin egy 
endogén purin nukleozid, amely négy, G proteinhez kapcsolt,  sejtfelszíni receptorhoz  (A1, A2A, A2B és 
A3) kötődve fejti ki hatásait. Bár az adenozin receptorok TNF-α termelést csökkentő hatását már leírták 
mikrogliákban, az IL-10 termelésre kifejtett hatását azonban ezidáig nem vizsgálták. Eredményeink 
alapján az adenozin növeli a Toll-szerű receptorok (TLR) ligandumaival aktivált mikrogliák IL-10 
termelését míg a gyulladáskeltő citokinek termelését gátolja. Farmakológiai kísérleteink igazolták, hogy 
az adenozin IL-10 termelésre kifejtett hatása az A2B receptoron keresztül történik. A hatás mechanizmusát 
vizsgálva kimutattuk, hogy az adenozin kezelés növeli az IL-10 mRNS mennyiségét egy cAMP 
reszponzív elem kötő protein (CREB) transzkipciós faktortól függő folyamat során. A CREB szerepét 
kromatin immunprecipitáció es RNS interferencia segítségével is megerősítettük. A továbbiakban 
kimutattuk, hogy az adenozin kezelés a p38 mitogén-aktivált protein-kinázt és a foszfatidil inozitol 3-
kinázt (PI3K) is aktiválja. Az adenozinnak a klasszikus módon, TH1 típusú citokinek jelenlétében, aktivált 
makrofágok gyulladáskeltő funkcióira kifejtett gátló hatása jól ismert az irodalomban. A makrofágok 
azonban TH2 típusú citokinek (IL-4 és IL-13) jelenlétében a klasszikustól jelentősen eltérő, úgy nevezett 
alternatívan aktivált fenotípust mutatnak. Az adenozin alternatívan aktivált makrofágokra kifejtett hatásai 
eddig nem ismertek. Eredményeink során kimutattuk, hogy IL-4 illetve IL-13 által aktivált 
makrofágokban adenozin kezelés hatására számos alternatív aktivációs marker kifejeződése nő, úgy mint 
argináz-1, mátrix metalloproteináz szöveti inhibitor-1 (tissue inhibitor of matrix metalloproteinase-1, 
TIMP-1) és makrofág galaktóz-típusú C-típusú lektin (macrophage galactose-type C-type lectin-1, mgl-1). 
Mivel ezt a hatást teljes mértékben kiküszöbölte az A2B receptor hiánya illetve farmakológiai gátlása, 
konklúziónk szerint az A2B receptor felelős az adenozin alternatív makrofág aktivációra kifejtett hatásáért. 
Kísérleteink során kimutattuk, hogy az ismert, alternatív aktivációban szerepet játszó transzkipciós 
faktorok közül egyedül a C/EBPβ (CCAAT-enhancer-binding protein ) volt nélkülözhetetlen az 
adenozin hatásához, míg a CREB illetve STAT6 (signal transducer and activator of transcription 6) nem 
játszott szerepet a folyamatban. Összefoglalva, eredményeink alapján az A2B adenozin receptor 
stimulációja növeli a klasszikus módon aktivált mikrogliák IL-10 termelését. Az A2B adenozin receptor 
stimulációja az IL-4 illetve IL-13 által indukált alternatív aktivációs markerek kifejeződését szintén 
megnöveli makrofágokban. 
